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Abstract
Chapter 1 provided the background for this thesis. The main goal of public
health policy is to promote, enhance and protect population health. This requires
information on the health status of the population, often referred to as the “burden
of disease”. Population health is a multifactorial phenomenon with many facets.
As a result, the disease burden of a population can be described by a variety of
indicators. As current health policy requires a global overview of public health,
combining morbidity and mortality and taking into account health-related quality
of life, so-called summary measures of population health (SMPH) are gaining
wider importance. Driven by the influential Global Burden of Disease projects
initiated in the early 1990s, the Disability-Adjusted Life Year (DALY) has become
the dominant SMPH. The DALY is a health gap measure, reflecting the number
of healthy life years lost due to disease and death. In the DALY philosophy, every
person is born with a certain numb...
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1
1.1 What is burden of disease?
The main goal of public health policy is to protect and promote population health. This
requires information on the health status of the population, often referred to as the “bur-
den of disease”. More than just the presence/absence of specific diseases and conditions,
disease burden encompasses a comprehensive quantification of the physical and psychoso-
cial health impact of diseases, conditions, and risk factors [1].
Evidence on the disease burden is important for decision-making processes within the
health sector. In order to make relevant decisions and set appropriate priorities, policy
makers need to be informed about the size of health problems in the population, the
groups that are particularly at risk, and the trends in the state of health over time. In
addition, an accurate estimate of the population’s health status can be used for determin-
ing the expected health care use and is vital for prioritizing effective interventions and
evaluating their impact and cost-effectiveness (e.g., by integrating them in generalized
cost-effectiveness analyses [2]).
The disease burden of the population can be described by a variety of indicators. In-
deed, public health is a multifactorial phenomenon with many facets and different ways
to measure it. Typical indicators of population health are life expectancy, cause-specific
mortality rates, numbers of new and existing cases of specific diseases (i.e., incidence and
prevalence), perceived health, the occurrence of physical and mental limitations and dis-
ability, but also more indirect measures, such as absenteeism, incapacity of work, and the
use of medical facilities and the associated costs. However, all these indicators highlight
only one facet of public health, i.e., either mortality or morbidity.
Historically, there has always been more of a focus on the collection of mortality and
cause of death data. Population health has therefore traditionally been summarized in
terms of mortality-based indicators, such as life expectancy. In many countries, however,
one has been confronted with an epidemiological transition of public health problems. The
importance of early mortality due to plagues and famines has been replaced by chronic,
non-communicable diseases, while communicable diseases remain a real threat, causing a
“double burden” [3]. Cardiovascular diseases and cancers have replaced infectious diseases
as the main causes of death. However, these diseases are also associated with an important
morbidity component, due to the life prolonging effect of continuously improving medical
practice [4]. Moreover, not only an extended life expectancy per se is aimed for, living
these extra years in good health has become just as important [5]. As a result, current
health policy requires a global overview of public health, one that combines morbidity
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and mortality and takes account of health-related quality of life (HRQoL; [6]).
Given the importance of combining morbidity and mortality, the last few decades have
seen important methodological advances in so-called summary measures of population
health (SMPH; [7]). By and large, SMPHs may be divided into two broad families,
namely health expectancies and health gaps. Metrics of each family combine morbidity
and mortality into a single figure. Health expectancy-based metrics, such as Disability-
Free Life Expectancy (DFLE), Healthy Life Years (HLY), and Disability-Adjusted Life
Expectancy (DALE), translate these indicators into a health-adjusted life expectancy;
health gap metrics, such as the Disability-Adjusted Life Year (DALY), translate these
indicators into a number of life years lost due to bad health and mortality.
Driven by the influential Global Burden of Disease (GBD) projects initiated in the
early 1990s, the DALY has become the dominant SMPH [8–11]. In the next section and
the remainder of this thesis, we will therefore focus on the DALY as main metric for
quantifying burden of disease.
1.2 Calculating disability-adjusted life years to quantify
burden of disease
1.2.1 Introduction
In the DALY philosophy, every person is born with a certain number of life years poten-
tially lived in optimal health. People may lose these healthy life years through living with
illness and/or through dying before a reference life expectancy. These losses in healthy
life years are exactly what is measured by the DALY metric. Ten DALYs, for instance,
correspond to ten lost years of healthy life, attributable to morbidity, mortality, or both.
On a population level, diseases with a higher public health impact will thus account for
more DALYs than those with a lesser impact.
DALYs have been the key measure in the different GBD studies, each presenting a
comprehensive assessment of the worldwide health impact of disease, injury and risk
factors [8–11]. Table 1.1 shows the most important diseases according to the different
GBD studies. Furthermore, various national and regional DALY calculations have been
performed to assess and monitor local health and to set priorities within the local health
sector (e.g., Melse et al. for the Netherlands [12], and Mathers et al. for Australia [13]).
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1 Table 1.1: Top three diseases according to different Global Burden of Disease (GBD) studies
GBD 1990 [8] GBD 2001 [9] GBD 2004 [10] GBD 2010 [11]
Lower respiratory in-
fections
Perinatal conditions Lower respiratory in-
fections
Ischaemic heart dis-
ease
Diarrhoeal diseases Ischaemic heart dis-
ease
Diarrhoeal diseases Lower respiratory in-
fections
Perinatal disorders Lower respiratory in-
fections
Unipolar depressive
disorders
Stroke
1.2.2 Basic DALY formulae
DALYs are composed of Years Lived with Disability (YLDs) and Years of Life Lost due
to premature mortality (YLLs).
YLDs, the morbidity component of the DALYs, are calculated as follows:
YLD = Number of cases×Duration till remission or death×Disability Weight (1.1)
The Disability Weight (DW) is a crucial component of the DALY calculation, as they
translate morbidity into healthy life years lost, thus enabling comparison of morbidity
and mortality. A DW, scaled from zero (perfect health) to one (worst possible health
state), can be interpreted as the proportional reduction in good health due to an adverse
health state. In the DALY mindset, this is set equivalent to losing the same proportion
of healthy life years over the course of the disability. Living ten years with a DW of 0.10,
or five years with a DW of 0.20, thus both correspond to losing one full healthy life year.
For example, a female patient develops severe alcohol use disorder at age 40 and conse-
quently dies at age 60. This condition has a DW of 0.55 [14], and is thus assumed to cause
a 55% reduction of good health, or, equivalently, a loss of 55% of the potential healthy
life years lived during the 20 years of suffering from this condition. The number of YLDs
for this patient (i.e., number of cases = 1) is therefore calculated as:
YLD = 1× (60− 40)× 0.55 = 11
YLLs, the mortality component of the DALYs, are calculated as follows:
YLL = Number of deaths× Residual life expectancy at the age of death (1.2)
The first GBD studies used the life expectancy at the age of death from the Coale-
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Demeny Model Life Table West. This table has a life expectancy at birth of 80 for males
and 82.5 for females [15]. In the latest GBD study, a new model life table was developed,
with a life expectancy at birth of 86 for both males and females (available as a supplement
in [1]). Furthermore, current World Health Organization (WHO) Global Health Estimates
are based on the projected frontier life expectancy for 2050, with a life expectancy at birth
of 92 for both males and females [16]. Alternatively, local life tables may be used instead
of standard life tables.
Continuing the aforementioned example, the residual life expectancy of a 60-year old
female is 25 years in the Coale-Demeny Model Life Table West. Dying at the age of 60
will thus cause a loss of 25 full life years potentially lived in optimal health (note again
that number of deaths = 1):
YLL = 1× 25 = 25
DALYs are simply the sum of the YLDs and YLLs:
DALY = YLD + YLL (1.3)
For our patient, this would mean 11 YLDs + 25 YLLs = 36 DALYs, which can be
interpreted as a loss of 36 healthy life years. These 36 years (DALYs) are composed of
the equivalent of 11 full healthy life years lost due to living in a less-than-optimal health
state (YLDs), and the actual 25 healthy life years lost due to premature death (YLLs).
In population-based burden studies, average DALYs are calculated for specific age and
sex strata, based on the total number of cases and deaths in each stratum, and the
average duration, age at onset and age at death in each stratum. Population totals are
then obtained by summing these stratum-specific DALYs.
1.2.3 Social weighting
The basic formulae for YLDs and YLLs may be extended by applying so-called social
weighting functions. This implies that not all life years lost will be valued equally, and
social weighting is therefore not universally accepted [17, 18].
Age weighting, as used in the initial GBD study and many ensuing studies, implies that
the value of life depends on age. A higher weight is given to the healthy life years lived
in the (assumed) socially more important life span between 9 and 56 [15].
5
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The standard age weighting formula is:
Cxe−βx (1.4)
with x the concerned age, and C and β constants commonly set to 0.1658 and 0.04.
Time discounting discounts years of healthy life lived in the future at a rate of (usually)
3%. This reflects similar practices in economic assessments, and would prevent policy
makers from saving resources for a future eradication program, instead of investing in
currently available, but less effective, intervention measures [15].
The standard time discounting formula is as follows:
e−r(x−a) (1.5)
with r the discount rate, x the concerned age, and a the age to which the burden will be
assigned.
Combining both social weighting functions gives the following extended YLD and YLL
formulae:
Y LD = N ×DW ×
∫ A+L
A
{
KCxe−βxe−r(x−a) + (1−K)e−r(x−a)
}
dx (1.6)
Y LL = M ×
∫ A+L
A
{
KCxe−βxe−r(x−a) + (1−K)e−r(x−a)
}
dx (1.7)
where N equals the number of cases, M the number of deaths, and DW the disability
weight. K is a modulating factor equalling one if age-weighting is applied and zero oth-
erwise; A and L represent, respectively, the age at onset and the duration (Eq. 1.6), or
the age at death and the life expectancy at the age of death (Eq. 1.7).
The subjective choices of whether or not to apply age weighting and time discounting
can have important effects on the DALY estimates. Only DALYs based on the same social
value choices should therefore be compared. For illustration, we calculated DALYs for our
example under different scenarios (Table 1.2). Figure 1.1 visualizes these results (note
that the integrals of Eq. 1.6 and Eq. 1.7 translate to areas under the curve). Table 1.3
presents the social value choices applied by the four different GBD studies.
Given the lack of consensus on social weighting, we recommend to calculate DALYs
under different scenarios, denoted DALY[K; r]. By calculating at least the DALY[0;0],
DALY[0;0.03], and DALY[1;0.03] scenario, comparability with most other studies is likely.
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Table 1.2: Years Lived with Disability (YLDs), Years of Life Lost due to premature mortality
(YLLs) and Disability-Adjusted Life Years (DALYs) for the alcohol use disorder
example under different social value choices
Scenario [K;r] Age Weighting Discount Rate YLD YLL DALY
DALY[0;0] No 0% 11.0 25.0 36.0
DALY[1;0] Yes 0% 12.3 16.7 29.1
DALY[0;0.03] No 3% 8.3 9.7 17.9
DALY[1;0.03] Yes 3% 9.5 6.7 16.2
age
DALY[0;0]
0 20 40 60 80
dis
ab
ility
 le
ve
l
YLD
YLL
age
DALY[0;0.03]
0 20 40 60 80
dis
ab
ility
 le
ve
l
YLD
YLL
age
DALY[1;0]
0 20 40 60 80
dis
ab
ility
 le
ve
l
YLD
YLL
age
DALY[1;0.03]
0 20 40 60 80
dis
ab
ility
 le
ve
l
YLD
YLL
Figure 1.1: Years Lived with Disability (YLD) and Years of Life Lost (YLL) for the alcohol
use disorder example under different social weighting scenarios. The top left
plot represents the basic Disability-Adjusted Life Year (DALY) calculation. The
bottom left plot includes age weighting; the curved black line is the age-dependent
zero disability level, while the straight grey line compares the situation without
age weighting. The top right plot includes a 3% time discount rate; the burden
is assigned to the year of disease onset (i.e., the age of 40). The bottom right
plot, finally, combines age weighting and a 3% time discount rate.
Table 1.3: Social value choices applied by different Global Burden of Disease (GBD) studies
Study Age Weighting Discount Rate Scenario[K;r]
GBD 1990 [8] Yes 3% DALY[1;0.03]
GBD 2001 [9] No 3% DALY[0;0.03]
GBD 2004 [10] Yes 3% DALY[1;0.03]
GBD 2010 [11] No 0% DALY[0;0]
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1.2.4 Presenting DALYs
DALYs can be expressed as an absolute number, thereby giving an idea of the total popu-
lation burden. They can also be expressed relative to the population, e.g., as the number
of DALYs per 1000 population. This enables a direct comparison of the burden suffered
by different populations. Finally, DALYs may also be expressed relative to the number of
cases. This allows comparisons of the impact of diseases at the patient-level, instead of
at the population-level.
All assumptions used in the DALY calculation should be explicitly mentioned, including
DWs, life expectancy table and social weighting functions. This ensures correct interpre-
tation of DALY estimates and reduces “error” variation between burden studies [19].
1.3 Understanding the burden of disease in Nepal: a call
for local evidence
1.3.1 Burden of Disease in Nepal
The importance of burden of disease estimates for the health policy-making process in
Nepal becomes evident from recent policy documents and recommendations. A compre-
hensive and strategic approach towards public health is a relatively recent phenomenon
in Nepal. The first National Health Policy (NHP) was adopted in 19911, and served as
a policy framework to guide the development of the health sector. The NHP was mainly
focused on increasing the health status of the rural population. To this end, it included
directives to establish health facilities at the Village Development Committee level and to
implement decentralization throughout the health sector. Based on the NHP, the Second
Long-Term Health Plan (SLTHP) 1997–2017 was drafted, which was the first document
to recognize the importance of prioritizing health sector needs, motivated by the scarce
human, financial and physical resources available2. In parallel with the development of
the SLTHP during the late 1990s, a comprehensive analysis of health care delivery in
Nepal was conducted by the World Bank, and in 2000 the results were presented in a re-
port entitled Operational Issues and Prioritization of Resources in the Health Sector [20].
Based on a situation analysis, the report makes several recommendations for the fur-
ther development of the Nepalese health sector, one of which was the establishment of
priorities:
“Because Nepal lacks the institutional or financial capacity to do everything
1http://mohp.gov.np/english/publication/national_health_policy_1991.php
2http://mohp.gov.np/english/publication/second_long_term_health_plan_1997_2017.php
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that needs to be done immediately, health system initiatives and interventions
will need to be phased in. [. . . ] Sequenced priority interventions that have
the strongest impact on health status need to be planned and given the man-
agement attention and financial resources necessary for their successful imple-
mentation.”
These recommendations were carried forward in the development of the Nepal Health
Sector Programmes (NHSP), short-term strategic frameworks for the further development
of the health sector. Within these programmes, disease burden is recognized as one of the
bases for setting programme priorities. The second NHSP Implementation Plan 2010–
2015 states, for example, that the “introduction of new and under-used vaccines will be
prioritised based on disease burden, financial sustainability and infrastructure” [21].
1.3.2 But where is the evidence?
Notwithstanding the importance of burden of disease estimates, Nepalese DALY estimates
are very scarce. The first national burden of disease study was conducted by the World
Bank in the 1990s, and its results appeared as an annex to the aforementioned situation
analysis report [20]. This study used mortality data from the United Mission to Nepal
hospitals and morbidity data from WHO community-based studies and national vector-
borne disease control programmes. Data on non-communicable diseases (NCDs) were
extrapolated from NCD burden of disease estimates for rural India. The study estimated
a national burden of disease for 1996 of 363 DALYs per 1000 population. The proportion
of total DALYs due to communicable, maternal/perinatal and nutritional conditions was
68.5%. Non-communicable and congenital diseases accounted for 22.8% of the burden,
injuries and violence for the remaining 8.7%. Based on a projected demographic shift due
to decreasing fertility rates, the study team predicted the national burden to decrease to
245 DALYs per 1000 in 2011. The proportions of the different disease categories were
projected to evolve to 61.4%, 28.6% and 10.0%, respectively, implying that the group of
communicable diseases would remain the dominant source of disease burden.
A second source of disease burden estimates for Nepal is the 2004 update of the WHO
GBD study [10]. This study estimated an overall age-standardized disease burden of 308
DALYs per 1000 in 2004, in line with the World Bank projections. In contrast to the World
Bank estimates, however, the majority of the burden was attributed to non-communicable
and congenital diseases (48.5%), followed by communicable, maternal/perinatal and nu-
tritional conditions (39.9%) and injuries and violence (11.6%). An important difference
between the World Bank and WHO studies is that the former was largely based on local
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data, whereas the latter was mainly based on regional extrapolations. Except for tu-
berculosis, malaria, HIV/AIDS and childhood-cluster diseases, the WHO study reported
low levels of evidence on mortality and morbidity for all other considered diseases and
disabilities. The cause-of-death distribution patterns of India and the Philippines were
therefore used as proxy for that of Nepal. Although Nepal is in certain aspects compara-
ble to these countries, most notably India, it is questionable to what extent their health
situations are similar. Such extrapolations must therefore be treated with caution. It is
for instance not clear whether or not Nepal is undergoing its demographic and epidemio-
logical transition at the same pace as India. A possible policy shift from communicable to
non-communicable diseases based on these estimates [22], should therefore be evaluated
with utmost care.
Indeed, the WHO GBD 2004 results seem to be refuted by the third and most recent
source of DALY estimates for Nepal, the comprehensive GBD 2010 study [11]. This study
concluded that between 1990 and 2010, the importance of communicable diseases has
decreased in favour of NCDs, but that even today lower respiratory infections, diarrheal
diseases, and neonatal encephalopathy (due to birth asphyxia or trauma) are still the
leading causes of healthy life years lost in Nepal. However, as GBD 2010 did not provide
its raw data, it remains unclear to what extent these conclusions were based on local data.
1.3.3 A call for local evidence
It is clear that local and reliable evidence on the burden of disease in Nepal is of great
importance in setting healthcare priorities and monitoring health trends. In this respect,
it is laudable that national burden of disease studies have recently been initiated by the
Nepal Health Research Council, with the support of the Ministry of Health and Popula-
tion [23, 24]. A first Assessment of Burden of Diseases in Nepal project was initiated in
2007, and was based on a nation-wide sample of primary mortality data collected through
the Motherhood Method [25], and complemented with secondary morbidity data. The
project is reported to be completed, but results have not yet been made available. In
2009, a second Assessment of Burden of Diseases in Nepal project was launched, focusing
on the Central Development Region of Nepal. The main aim of the study was to ob-
tain mortality and cause-of-death estimates through verbal autopsy questionnaires. This
project is currently reported to be nearing completion.
Notwithstanding these current efforts, there are still huge knowledge gaps with regards
to Nepal’s health status. More and better local information is therefore urgently needed.
This can and should be achieved at the different levels of the data generation process:
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There should be an increased focus on data collection in Nepal. Investments
in national community-based surveys and longitudinal studies would generate new
evidence bases upon which future policies can be drafted. Nepal is currently partic-
ipating in Demographic and Health Surveys [26], but these only cover a fraction of
the entire health spectrum, and are mainly focused on child and maternal health.
Existing data generation mechanisms should be further strengthened. In this
respect, the efforts to improve the Health Management Information System [27, 28],
the official passive surveillance system of Nepal, should continue to be actively
encouraged and supported. Capacity strengthening at all levels of the decentralized
data collection system will need to be an important part of these efforts.
Existing data should be made publicly available and integrated. The health
system in Nepal is multi-sectorial, with major contributions by private and NGO
providers, in addition to the government. As a result, various government agen-
cies, development partners, I/NGOs, local and international academia are actively
collecting data, but these are not always made available to the general public. Dif-
ficulties in obtaining health statistics from the private sector has been recognized
as an important factor limiting the evidence base in Nepal [29]. With regards to
academic research, improved digital thesis libraries could help to disseminate the
information produced by the various Bachelor, Master and PhD students in Nepal.
Available data should be used in the most optimal way. Local capacity for trans-
forming the available data into policy-relevant information, such as DALYs, should
therefore be further strengthened. There are a number of international projects
which can assist in the translation of incidence data into burden of disease esti-
mates and provide context. This includes the GBD 2010 study, which performed a
comprehensive and consistent revision of disability weights, a fundamental input into
DALY calculations [14]. Global and regional estimates of the incidence and burden
of disease by WHO initiated Epidemiology Reference Groups for children (CHERG)
and foodborne hazards (FERG) can provide issue specific information [30].
1.3.4 The way forward
By strengthening the local evidence base, we can continually improve our understanding
of the burden of disease in Nepal. By effectively translating this evidence into policy,
we may furthermore assure that this burden can be addressed in the most efficient way.
All stakeholders, including policy makers, development partners, researchers and public
health workers, should therefore join forces to accomplish these goals.
11
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Appendix. Calculating DALYs in R
The following R code can be used to calculate DALYs:
## Helper function (calculates integral in Eq. (1.6) and (1.7))
f <-
function(x, K, C = .1658, beta = .04, r, a) {
K * C * x * exp(-beta * x) * exp(-r * (x - a)) +
(1 - K) * exp(-r * (x - a))
}
## Burden calculation function (Eq. (1.6) and (1.7))
burden <-
function(N, DW, A, L, K, r, a) {
N * DW * integrate(f, lower = A, upper = A + L, K = K, r = r, a = a)$value
}
The following R code implements the alcohol use disorder example:
## Select any of the following scenarios
K <- 0; r <- 0 # DALY[0;0]
K <- 1; r <- 0 # DALY[1;0]
K <- 0; r <- 0.03 # DALY[0;0.03]
K <- 1; r <- 0.03 # DALY[1;0.03]
## Calculate DALY = YLD + YLL
burden(N = 1, DW = 0.55, A = 40, L = 20, K = K, r = r, a = 40) + # YLD
burden(N = 1, DW = 1.00, A = 60, L = 25, K = K, r = r, a = 40) # YLL
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Objectives
The introduction has identified the importance of burden quantification for guiding health
policy and breaking the cycle of indifference and under-funding, especially in resource-
poor settings such as Nepal. However, although the DALY has become the key metric for
quantifying disease burden, its use is hampered by a limited standardization of method-
ologies.
The main objective of this thesis is therefore two-fold:
To contribute to the standardization of the DALY metric
To achieve this objective, we will propose a general approach for conducting DALY-
based disease burden studies (Chapter 3); review which sources of uncertainty
exist and how these can be dealt with (Chapter 4); and develop a standardized
tool for DALY calculations (Chapter 5).
To quantify the burden of zoonoses in Nepal
To achieve this objective, we will quantify the burden of parasitic zoonoses in Nepal
(Chapter 6) and study the burden of rabies (Chapter 7).
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DALY calculation in practice: a
stepwise approach
Adapted from
Devleesschauwer B, Havelaar AH, Maertens de Noordhout C, Haagsma JA, Praet
N, Dorny P, Duchateau L, Torgerson PR, Van Oyen H, Speybroeck N (2014) DALY
calculation in practice: a stepwise approach. Int J Public Health 59:571–4.
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3.1 Introduction
The philosophical and methodological aspects of the Disability-Adjusted Life Year (DALY)
calculation have been described (and debated) in great detail [15, 31, 32], and have been
summarized in the introductory chapter. The steps preceding the actual calculation, how-
ever, remain less well documented. This Chapter tries to address this gap by presenting a
general approach towards a DALY-based burden of disease study. This approach consists
of five consecutive steps, and is presented in Figure 3.1.
Study population definition 
Disease model definition  
Data collection Data adjustment 
DALY calculation 
Figure 3.1: Stepwise approach towards a DALY-based burden of disease study.
3.2 Step 1: Study population definition
As a first step, the context in which the burden assessment study will take place should
be clearly defined. The target population must be delineated by defining study area and
time period. The latter may be one specific year, or a range of years, which can then be
used to calculate the average burden of that time period.
3.3 Step 2: Disease model definition
The disease model (also called outcome tree) serves as a guide through the further process
of the study. Figure 3.2 presents the causal chain of disease. In general, risk factors
increase the risk of disease, either directly or indirectly through facilitating exposure to
biological, chemical or physical hazards. The course of disease is characterized by different
health states (e.g., acute or chronic phases, short-term or long-term sequelae), possibly
having different severity levels. A disease model is a schematic representation of the
different health states associated with the concerned cause of disease burden, and the
possible transitions between these states.
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Recovery Death 
Diseased 
Hazard 
Risk factor 
Healthy 
Figure 3.2: Generic causal chain of disease.
Depending on the cause of interest, i.e., the disease as such, the hazard or the risk
factor, three different approaches may be distinguished:
Outcome-based disease models represent different health states of diseases, irrespec-
tive of the possible (infectious or non-infectious) aetiologies. For example, a disease
model for the burden of diarrhoea could describe different diarrhoea severity lev-
els (mild, moderate, severe), contributing Years Lived with Disability (YLDs), and
diarrhoea-related death, contributing Years of Life Lost (YLLs) [33]. Soerjomataram
et al. [34] present generic outcome-based disease models for cancer, including disease
progression phases and sequelae.
Hazard-based disease models represent different health states associated with haz-
ards such as biological or chemical agents or traumas [35]. For example, Campylobac-
ter infection causes diarrhoea, but also other health states, such as Guillain-Barre´
Syndrome (GBS) [36]. The disease model would thus consist of the different as-
sociated symptoms (contributing YLDs), and death attributable to each symptom
(contributing YLLs).
Risk factor-based disease models represent different health states associated with
risk factors. For example, a disease model for unsafe water would include the health
effects associated with feco-oral pathogens, including Campylobacter, other diar-
rhoeal pathogens and soil-transmitted helminths [37].
A hazard-based disease model for Campylobacter infection is given in Figure 3.3. This
model includes diarrhoea, possibly progressing from acute to chronic stages and to death;
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GBS occurring in a mild or severe form, the latter being able to cause death; and reactive
arthritis. Other disease models can be constructed in a similar way. Disease models
can be obtained from previous burden studies. However, new insights might indicate an
updated disease model requiring data from a systematic review of relevant clinical and
epidemiological aspects.
Campylobacter 
Diarrhoea 
(acute) 
Diarrhoea 
(chronic) 
Death 
GBS 
(mild form) 
GBS 
(severe form) 
Death 
Reactive 
Arthritis 
Figure 3.3: Hazard-based disease model for Campylobacter infection. GBS = Guillain-Barre´
Syndrome.
3.4 Step 3: Data collection
This step is often the most difficult and time-consuming one. It is also the most crucial
one, as the quality of the final DALY estimate directly depends on the quality of the
data. Ideally, the necessary data should be collected through a systematic review of peer-
reviewed literature and various sources of grey literature, including government agencies,
non-governmental organizations and academia. An important guide for conducting and
reporting systematic reviews is the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement [38]. As much as possible, collected data should be
stratified by age and sex, as this will yield a more precise overall estimate and will en-
able to study the burden by age and sex. Further stratification by other parameters can
also be useful, and could allow a breakdown of disease burden by sub-region, occupation,
socio-economic status, etc.
Extrapolation models may be needed when literature searches cannot provide essential
data. These models estimate parameters from data of neighbouring regions or other time
periods. The external data used must thus be representative of the selected population,
region and time. Where no empirical data can be identified, expert elicitation may be
applied (see [39] for a guide).
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In general, three groups of data need to be collected:
3.4.1 Demographic data
DALY calculations require the total number of males and females, per age group, of
the selected area and time period. These data can be obtained from national statistical
bureaux or from the United Nations Statistics Division1. A second required source of
demographic data is the life expectancy table. In order to enhance comparability, the life
expectancy at the age of death is generally drawn from standard life expectancy tables
(Chapter 1). However, local life expectancy tables may also be used, in particular when
within-country disease ranking is an important objective. Local life tables are typically
available from national statistical bureaux.
3.4.2 Epidemiological data
The most important data for DALY calculations are the number of cases in the different
health states defined by the disease model, including death. Most often, the number of
incident cases is considered, although DALYs may also be calculated based on the num-
ber of prevalent cases (see [40] for a comparison). In the following, we will assume an
incidence perspective.
The number of incident cases is the product of the incidence rate and the population
size. Depending on data availability, there are three approaches to obtain incidences of
the individual health states in the disease model:
1. Direct approach: The incidence of a health state is directly available, e.g., through
a disease or mortality register. In our example (Figure 3.3), this would be the
case if a prospective population-based study directly estimated the incidence of
Campylobacter-associated GBS.
2. Attribution approach: The incidence of a health state is obtained from the overall
incidence of the given health state (i.e., regardless of aetiology), and an attribution
probability (not applicable for outcome-based disease models):
Overall incidence health state ×
Proportion attributable to hazard or risk factor
1http://data.un.org/
21
DALY calculation in practice: a stepwise approach
3
The incidence of GBS due to Campylobacter can for instance be obtained by multi-
plying the overall incidence of GBS in the population to the proportion of Campy-
lobacter-attributable GBS. In risk factor-based disease models, the proportion of
cases attributable to the risk factor is commonly referred to as the Population At-
tributable Fraction [41].
3. Transition approach: The incidence of a health state can be obtained from the
previous incidence in the model. Two scenarios are possible:
Overall incidence burden cause ×
Probability of transition to health state
Incidence health state ×
Probability of transition to next health state
The first scenario would imply that we model the incidence of Campylobacter-
associated GBS on the overall Campylobacter incidence in the population and the
probability of developing GBS after Campylobacter infection. The second scenario
would imply, for instance, that we model the chronic diarrhoea incidence by mul-
tiplying the acute diarrhoea incidence by the probability of progressing from acute
to chronic diarrhoea.
Possibly, epidemiological estimates can be derived through different approaches. In this
case, cross-validation of the different estimates can be performed, which can strengthen
their reliability.
3.4.3 Disease severity data
DALY estimates incorporate the severity of the health states through their duration and
disability weight (DW). The former can be obtained through hospital registers, literature
reviews, or expert elicitation. The latter are most commonly derived from Global Burden
of Disease studies [14] or the Dutch Burden of Disease study Stouthard et al. [42]. Essink-
Bot & Bonsel [43] describe methods for DW derivation.
3.5 Step 4: Data adjustment
Potential data biases should be critically appraised. Under-reporting and under-ascertainment
are well-documented sources of bias [44]. Misclassification bias due to imperfect diagnostic
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tests can be amended using various statistical techniques [45]. Finally, coherence in differ-
ent epidemiological parameters for non-infectious diseases can be assessed using DisMod
software [46].
3.6 Step 5: DALY calculation
Once all required data have been gathered, the actual DALY calculation can commence.
We have provided a technical summary of DALY calculations in section 1.2 of the Introduc-
tion. In Chapter 4, we will provide an overview of parameter, model and methodological
uncertainties related to DALY estimations, and propose ways for addressing these uncer-
tainties. Before the start of this thesis, however, there were no DALY calculation tools
available to perform stochastic DALY calculations. Indeed, most users had made their
own calculation model, either in a programming language such as R, or in Microsoft Excel
with add-ins enabling Monte Carlo simulation. Although flexible, these methods do not
guarantee methodological transparency. To address this gap and to improve consistency
in DALY calculations, we developed a free and open-source tool for stochastic DALY
calculations in R. This tool, called the DALY Calculator will be introduced in Chapter 5.
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calculations
Adapted from
Devleesschauwer B, Maertens de Noordhout C, Beutels P, Bilcke J, Briggs A, Dorny
P, Duchateau L, Havelaar AH, Smit GSA, Torgerson PR, Speybroeck N. Quantifying
uncertainties in Disability-Adjusted Life Year calculations: a systematic review of burden
of disease studies. In preparation.
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4.1 Introduction
In recent years, the Disability-Adjusted Life Year (DALY) has become one the most im-
portant metrics for quantifying burden of disease. DALYs are defined as the number of
healthy life years lost due to living with disease and/or dying before a predetermined life
expectancy. Causes inferring more morbidity or mortality will therefore attribute more
DALYs, making the DALY a natural currency for measuring and comparing burden of
disease. DALYs may also be used as effect measure in health impact assessment and
cost-utility analyses.
As with any population health metric, DALYs are subject to data uncertainty and
modelling choices. The resulting DALY estimate is thus hardly ever a single, fixed value,
defined with perfect accuracy and precision. In a practical guide on accounting for un-
certainty in decision-analytic models, Bilcke et al. [47] classified uncertainty into three
categories. Parameter uncertainty relates to uncertainty about the true value of the
model parameters; structural or model uncertainty relates to uncertainty regarding the
model structure; and methodological uncertainty relates to uncertainty due to normative
or subjective modelling choices.
The aim of this paper is to explore through a systematic review of burden of disease
studies how the aforementioned categories of uncertainty apply to DALY calculations,
and to review how these sources of uncertainty have been dealt with in DALY calculation
studies. We conclude by making recommendations on how to quantify uncertainties in
DALY-based burden of disease studies.
4.2 Materials and Methods
A systematic review was conducted of peer-reviewed literature published from 1994 to
2013, i.e., the 20-year period following the introduction of the DALY metric. Four schol-
arly databases, i.e., PubMed1, Asia Journals Online2, African Journals Online3 and Latin
America Journals Online4, were searched using the following search terms: “DALY”;
“DALYs”; “disability-adjusted life year”; “disability-adjusted life years”; “disability ad-
justed life year”; “disability adjusted life years”; “YLD”; “YLDs”; “years lived with dis-
ability”; “YLL”; “YLLs”; “years of life lost”. When full texts could not be retrieved online,
authors were contacted by email and requested to share a full text version.
1http://www.ncbi.nlm.nih.gov/pubmed
2http://www.asiajol.info/
3http://www.ajol.info/
4http://www.lamjol.info/
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After generating a set of unique titles, we screened titles, abstracts and, if needed, full
texts, for eligibility. In a first step, we only retained papers that presented unique DALY
calculations for the purpose of disease burden estimation. We therefore excluded papers
that did not present new DALY calculations, as well as DALY-based cost-utility and
health impact assessment studies. In a second step, we retained papers that presented
burden of disease assessments for current populations, thus excluding patient-level studies
and burden projections. We also excluded studies applying different YLL definitions than
the standard expected YLL introduced by Murray [15]. Studies focusing on risk factors
were also excluded as uncertainty in such studies has recently been reviewed by Knol et
al. [48] and Pru¨ss-Ustu¨n et al. [49]. Finally, studies based on quantitative risk assessment
or life cycle assessment were excluded as they apply specific methodologies and thus are
not representative for burden of disease studies. Although the search terms were in En-
glish, no restrictions were placed on the language of retrieved publications. Screening was
conducted independently by two researchers (BD, CMdN), and any disagreements were
solved through discussion and if needed through a third researcher (NS).
For each of the eligible papers, a narrative summary was made of the sources of un-
certainty, and information was extracted on how parameter, model and methodological
uncertainty were dealt with. As in the screening step, data extraction was performed inde-
pendently by two researchers (BD, CMdN), and any disagreements were solved through
discussion and if needed through a third researcher (NS). Manuscripts written in lan-
guages not mastered by the data extractors or their colleagues were translated using
Google Translate.
In addition to the systematic review, we also reviewed how uncertainties were handled
in different Global Burden of Disease (GBD) studies, i.e., GBD 1990, GBD 2001, GBD
2010 and the WHO Global Health Estimates (GHE).
4.3 Results
4.3.1 Systematic review
In total, we could retain and evaluate 228 papers. The number of burden of disease studies
increased exponentially from 1994 to 2013, with almost half of the papers being published
in the last five years. Most of these were written in English (217), followed by Spanish (8),
Chinese (7), French (2), Portuguese (2), and Dutch, Japanese, Korean, Polish and Swedish
(1 each). The majority of the studies presented general burden of disease assessments (78);
74 assessed the burden of communicable diseases, 68 of non-communicable diseases and 28
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of injuries. Twenty-four presented a global burden assessment; others presented a burden
assessment for a single country or region, with the top five being The Netherlands, China,
Spain, Australia and South Korea (Figure 4.1).
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Figure 4.1: Barplot of geographical areas for which burden of disease study were performed.
4.3.2 Sources of uncertainty in DALY calculations
In line with the classification of Bilcke et al. [47], we distinguish between parameter
uncertainty, model uncertainty and methodological uncertainty.
Parameter uncertainty
Parameter uncertainty relates to a lack of knowledge on the true value of model param-
eters. DALY calculations require demographic, epidemiological, and severity parameters
(Chapter 3), each of which can be uncertain. Severity parameters, such as duration
and disability weight, relate to individual patients and can therefore also be variable.
Variability, sometimes referred to as stochasticity or first order uncertainty, distinguishes
itself from uncertainty in that it is an inherent property of populations, and cannot be
reduced by gaining more information, e.g., by increasing the sample size.
In general, parameter uncertainty results from sampling error and/or systematic error
or bias. Sampling error is well known and well-studied by statisticians. It arises when a
parameter is inferred from a representative sample of the population of interest. It can
be modelled directly, for instance by assuming a Binomial distribution for a prevalence
estimate obtained by testing a certain population sample. At a different level, when
parameters are modelled from a statistical model, the resulting standard errors also re-
flect this sampling error. Systematic error, on the other hand, is less well-studied, but is
potentially much more important. In DALY calculations, systematic error is very often
related to the extrapolation of parameter values from non-representative populations or
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time periods. The most extreme form of extrapolation occurs when there is a complete
lack of data, a common situation in global or regional burden of disease studies. It is
not clear to what extent these alternative settings are representative for the concerned
setting, and different alternative settings may provide different parameter values, related
to different levels of bias. Misclassification, underreporting and under-ascertainment are
typical and common sources of systematic error in epidemiological parameters such as
prevalence, incidence and mortality [45, 50]. Garc´ıa-Fulgueiras et al. [51, 52] for instance
highlight uncertainty in hepatitis C and B mortality rates due to misclassification as aids,
and Ditsuwan et al. [53] discuss uncertainty in the number of deaths from road traffic
accidents due to the presence of ill-defined causes (so-called “garbage codes”) in vital
registration data. Formally, a distinction is made between under-ascertainment, referring
to cases not seeking health care, and underreporting, referring to healthcare seeking cases
that do not get reported to national surveillance systems [35]. In practice, however, many
authors combine both phenomena under the heading of “underreporting”. Indeed, uncer-
tainty in the level of underreporting appears to be one of the most commonly highlighted
sources of uncertainty. The level of underreporting is commonly expressed as the ratio of
the presumed total number of cases over the reported number [54], referred to by different
authors as the underreporting factor, multiplier, expansion factor or multiplication factor.
A specific problem related to parameter uncertainty arises when uncertainty is corre-
lated. This may be the case if DALYs are calculated per age and sex group, but parameters
are only available at a less granular level. In GBD studies, this problem occurs when,
instead of country-specific parameters, regional or global parameters are used and applied
to each of the concerned countries. Such issues may be described as stratification uncer-
tainty: uncertainty arising because the level of detail required in the DALY calculations
does not match the level of stratification in the data (Chapter 5).
Model uncertainty
DALY calculations follow a disease model or outcome tree, i.e., a schematic representation
of health states that are causally related to the risk factor, hazard or disease of interest
(Chapter 3). Uncertainty in this disease model may arise when there is insufficient or
conflicting evidence on the causal relation of certain symptoms. Such uncertainty is com-
mon for long-term outcomes of infections, such as cirrhosis and hepatocellular carcinoma
following hepatitis C and B infection [52], or post-infectious irritable bowel syndrome fol-
lowing giardiosis [55]. Model uncertainty in DALY calculations may also originate from
health states being controversial due to ethical reservations. In this respect, Jamison et
al. [56] discussed the inclusion of stillbirths in GBD assessments.
29
Dealing with uncertainties in DALY calculations
4
A second source of model uncertainty can be linked to the epidemiological data used
in the DALY calculations. Often the available data come with a lot of restrictions, and
several assumptions need to be made to transform these into useable numbers. Whether
or not data should be corrected for underreporting or misclassification may for instance
become a source of model uncertainty.
Methodological uncertainty
The DALY metric encapsulates various methodological choices, often referred to as value
choices. Each of these choices are subjective, as there is no intrinsically correct choice.
As a result, different choices are being made, and contested, in literature.
The morbidity component of the DALY metric, the Years Live with Disability (YLDs),
is defined as the number of incidence cases multiplied with the duration and disability
weight (DW) of the health state. DWs value the loss in health-related quality of life
(HRQoL) due to a given health state. Different methods exist for deriving DWs, based
on either an econometric or psychometric philosophical perspective on HRQoL [57, 58].
Also, subjective choices need to be made on which population’s values to use: those of
patients, lay people, or disease experts? Phanthunane et al. [59] for instance compared
DWs for schizophrenia elicited from both patients and clinicians using different multi-
attribute utility instruments. Furthermore, DWs may be corrected for multimorbidity,
but again, different methods have been proposed, ranging from the use of arbitrary at-
tribution factors [60], over worst case or multiplicative approaches [1, 13], to regression
models [61, 62]. Finally, when DWs are not available for specific health states, “proxy”
DWs are commonly derived by mapping the concerned health state to alternative health
states for which DWs are available. LaBeaud et al. [63] for instance present a set of proxy
DWs for arbovirus-related long-term sequelae, showing the uncertainty induced by the
need to map to analogous health states.
The YLL component of DALYs is calculated as the number of deaths multiplied by the
residual life expectancy at the average age of death. Different possibilities exist regarding
the choice of the life expectancy table. The use of local (e.g., national) life expectancy
tables has been propagated to reflect the local epidemiological situation [64–71]. Local
life expectancy tables have also been used for specific population subgroups, such as eth-
nic minorities in Australia [72], or for future populations, such as the French population
in 2020 [73]. Some authors further adapted local life expectancies to reflect reduced life
expectancy in fatal cases, assuming that these cases had underlying diseases [36, 74, 75].
Matemba et al. [76] used the opposite approach, by adapting the local life expectancy
table to estimate the burden of sleeping sickness if the HIV/aids epidemic had not oc-
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curred. In addition to these local life expectancy tables, the use of so-called “standard”
life expectancy tables has been promoted to ensure comparability across populations. To
date, however, there are three different “standard” life expectancy tables in use. The
standard life expectancy table used in the original formulation of the DALY metric had
a life expectancy at birth of 80 for males and 82.5 for females [15]. Recently, a new,
synthetic standard life expectancy table was introduced in the GBD 2010 study, with a
life expectancy at birth of 86 for both males and females [1]. The WHO GHE, finally, are
based on a standard life expectancy table reflecting the projected life expectancy in 2050,
and has a life expectancy at birth of 92 for both males and females [16].
The basic DALY formulas can be extended by including so-called social weighting func-
tions (Chapter 1, Section 1.2.3). Age weighting gives different weights to healthy life
years lived at different ages. Time discounting gives exponentially decreasing weights to
healthy life years lived in the future. Whether or not these social weighting functions
should be used remains a subjective choice, and has indeed been the subject of various
discussions [17, 18]. Furthermore, there is no consensus on the exact parameterization of
these social weighting functions. Although age weighting commonly follows the original
formulation, some authors proposed alternative formulations that better reflected their
local situation [77]. When discounting time, the standard choice has been to apply a 3%
discount rate, but certain national instances propose different weights, e.g., 1.5% in The
Netherlands and 3.5% in the United Kingdom [55].
The GBD 2010 study introduced a prevalence-based version of the YLD, defined as the
product of number of prevalent cases and DW [1]. The possible choice between an inci-
dence and prevalence perspective introduces a new source of methodological uncertainty.
4.3.3 Dealing with uncertainties in DALY calculations
Most authors seem to be aware of the uncertainty in their final DALY estimates and
discuss uncertainty as an important study limitation or indicate that their estimates are
conservative. However, only in 105 studies (46%) some sort of uncertainty quantification
had been performed. Parameter uncertainty was quantified in 77 studies (34%), model
uncertainty in 22 studies (10%), and methodological uncertainty in 60 studies (26%).
Different approaches have been used to deal with these sources of uncertainty, although
the nomenclature used to describe these methods was found to be heterogeneous.
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Parameter uncertainty
By far the most powerful method to deal with parameter uncertainty is probabilistic sen-
sitivity analysis (PSA), sometimes also called uncertainty analysis or uncertainty propa-
gation. In PSA, the uncertain parameters are represented by uncertainty distributions,
thereby following the Bayesian definition of probability as a degree of belief instead of
a long-term frequency. PSA uses Monte Carlo simulations, or parametric bootstrap, to
sample random values from the specified uncertainty distributions. At each iteration, the
sampled values are used to calculate a DALY estimate. The combination of iterations
therefore results in a distribution of DALY estimates, reflecting the joint uncertainty in
the input parameters. PSA was applied in 33 studies, or 33% of studies quantifying pa-
rameter uncertainty.
Some authors included parameters in their PSA that they considered to be variable,
but not uncertain. Nevertheless, it is possible to separate both processes, using second
order or two-dimensional Monte Carlo [74, 78]. Zhao et al. [79] introduced the jackknife
method for estimating variability around DALY estimates. They re-sampled their data
by deleting one subgroup of records at a time and recalculated the DALY measures at
each iteration.
A less powerful method for evaluating parameter uncertainty is scenario analysis or
one-way sensitivity analysis. In this approach, one parameter is changed at a time by
taking a value at the extreme of the distribution while keeping the other parameters fixed
at their central value. This approach was also applied in 33 studies (33%), often as the
only means of parameter uncertainty quantification, but sometimes in combination with
PSA when some parameters had large uncertainty due to strongly contradicting data
sources [36, 74, 80, 81].
Some authors used a substitution method for estimating DALY uncertainty intervals.
In this approach, an uncertainty interval for the DALY estimate is obtained by calcu-
lating DALYs for the lower and upper confidence limit of a specific input parameter. It
transposes the standard error or confidence interval of an input parameter to the DALY
estimate. Although this approach is simple and appealing, it will lead to biased results
if more than one parameter is considered uncertain. Also, the method requires that the
DALY estimate is a monotonic function of the parameter for which the uncertainty inter-
val is available [82].
To evaluate which uncertain parameters contribute most to the uncertainty in the final
DALY estimate, variable importance analysis techniques can be applied. To add to the
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confusion, these are often also called sensitivity analyses. Certain authors calculated stan-
dardized regression coefficients, by regressing the standardized input parameters against
the (standardized) simulated DALYs obtained with PSA [83–86]. The resulting regression
coefficients reflect the expected (standard deviation) change in DALY per standard devi-
ation change in the respective input parameter. Other authors calculated as a measure of
influence the ratio of the change in DALY observed in a scenario analysis over the baseline
DALY estimate [87–90].
Most authors who assessed parameter uncertainty reported using Excel with a specific
add-in for Monte Carlo simulations, such as @RISK, Crystal Ball, PopTools or Ersatz. A
limited number of authors used programming languages such as Analytica, SAS, or R. Late
versions of DisMod-II also appear to have been used for PSA [91, 92]. The computational
framework set up for the GBD 2010 study allows propagating uncertainty through the
different modelling steps [1]; however, it is not entirely clear to what extent parameter
uncertainty is propagated to the end result, and at which modelling steps uncertainty is
propagated or ignored.
Correlation of uncertainty was not explicitly addressed by any of the reviewed papers.
Nevertheless, the manual of the DALY Calculator discusses stratification uncertainty and
propose an approach for dealing with it (Chapter 5). Stratification uncertainty would
occur when an obtained uncertainty distribution for parameter X relates to a general
population, say both males and females, but should be used for calculating DALYs for a
specific population, say males or females. If this distribution would have a variance σ2,
simulating independent samples from this distribution, and adding these up, i.e., ignoring
stratification uncertainty, would yield a variance of var(X) + var(X) = σ2 + σ2 = 2σ2.
However, taken into account the perfect correlation, they propose to sample once from
this distribution, and use the vector of sampled values twice. This would yield a variance
of var(2X) = 4σ2. By extending this example, it can be shown that the variance for n
strata is n2σ2, whereas it would be nσ2 if simulated independently. In other words, not
accounting for stratification uncertainty would underestimate the overall uncertainty with
a factor n.
Quantifying uncertainty resulting from extrapolation from non-representative popula-
tions or time periods is much more challenging. Torgerson & Mastroiacovo [93] modelled
the uncertainty in congenital toxoplasmosis incidence in countries without data as a uni-
form distribution defined by the lowest and highest observed incidence in neighbouring
countries. In GBD 2010, DisMod-MR is designed to extrapolate across time and space,
using either mixed models or space-time regression [1].
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Model and methodological uncertainty
Both model and methodological uncertainty can be quantified through scenario analysis,
in which DALYs are calculated under different assumptions and compared. Of the 22
studies that quantified model uncertainty, 10 had performed scenario analyses to assess
the effect of correcting for underreporting. Of the 60 studies that quantified methodolog-
ical uncertainty, the effects of age weighting and time discounting were most commonly
assessed (30 studies each), followed by different choices for DW (19) and life expectancy
table (14).
In theory, model and methodological uncertainty may also be assessed through PSA,
by parameterizing the uncertain model elements or the methodological choices. Whether
or not underreporting should be corrected for, could for instance be parameterized by
specifying an uncertainty distribution on the underreporting factor with a minimum of one
and a certain maximum. Indeed, Luz et al. [94] performed a PSA with a multiplication
factor ranging from 0.3 to 10, thus accounting for overreporting over correct reporting
to underreporting. Including or excluding a certain health state could for instance be
modelled as a Bernoulli random variable with inclusion probability pi. The resulting
distribution of simulated DALY estimates will then be a combination of different disease
model assumptions. This approach however has not yet been applied in burden of disease
studies.
4.4 Discussion
Identifying and addressing uncertainties in DALY calculations is crucial for conveying the
strength of evidence of the estimate and for allowing proper comparisons between studies.
As a result, the validity of the estimates will be strengthened, increasing their usefulness
for influencing decision-making processes. Additionally, it will help to identify knowledge
gaps and provide opportunities for further research. Nevertheless, uncertainty in DALY
calculations so far received little attention. To date, the most comprehensive review of
uncertainty in DALY estimations focused on the environmental burden of disease, i.e.,
the burden attributable to environmental risk factors [48]. Other researchers focused
on uncertainties in DALY calculations in the context of health impact assessments [95]
and cost-utility analyses [96]. Two recent systematic reviews, on general and foodborne
burden of disease studies, covered methodological choices and uncertainty analyses, but
were limited in scope and detail [19, 97]. To the best of our knowledge, this systematic
review therefore provides the most comprehensive and detailed assessment of uncertainty
in DALY calculations for assessing burden of disease.
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By reviewing the disease burden studies published in the first two decades after the
introduction of the DALY metric, we observed that most authors were aware of the un-
certainties inherent to DALY estimations. However, only half of the studies presented
some kind of quantification of these uncertainties. Nevertheless, methods for quantifying
parameter, model and methodological uncertainty are available and commonly used in
other, closely related fields, such as risk assessment and health economics [98, 99]. Also,
several tools already exist for quantifying and analysing uncertainty in DALY calcula-
tions, including the DALY Calculator in R (Chapter 5), Qalibra [100], and the GBD 2010
methodological framework comprising DisMod-MR [1]. However, only the DALY Calculator
is available to the general public.
Our review also identified several avenues for further research. Parameter uncertainty
due to extrapolating data from (spatially and/or temporally) non-representative popula-
tions is common in DALY calculations, but is difficult to quantify. So far only few authors
have addressed this issue [1, 93], and further experimental research is needed to under-
stand the performance of their proposed methods. Second, model uncertainty can only be
realistically quantified if there exists a realistic set of models. Although this is a general
problem, which in fine cannot be resolved, it is unfortunate that disease models appear
to be reused without critical assessment of their accuracy or validity. Finally, to address
methodological uncertainty, Briggs et al. [101] argued for the definition of a “reference
case”, a baseline scenario against which all methodological choices can be assessed. In
the context of the DALY metric, however, this seems problematic, as methodologies have
been gradually changing since its inception. The current consensus seems to be that age
weighting and time discounting should no longer be part of the reference case, but less
agreement exists over which DW methodology and life expectancy table to use.
Notwithstanding the above limitations, researchers should be aware of the various pos-
sible sources of uncertainty when calculating DALYs, and should, in order of importance,
identify, quantify and analyse these uncertainties. We recommend researchers to quan-
tify parameter uncertainty using PSA, if possible complemented by a variable importance
analysis. Although scenario analyses could also be used, this approach is less powerful in
quantifying joint uncertainty, and would lead to too many scenarios if several parameters
are considered uncertain. On the other hand, we do recommend researchers to quantify
model and methodological uncertainty using scenario analyses, because of practical and
philosophical reasons. Indeed, model and methodological uncertainty relates to choices
that need to be made, and that will be made differently by different researchers. Only
scenario analyses allow comparing estimates generated under the same set of assumptions.
Philosophically, and especially for methodological uncertainty, combining a selection of
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choices in a PSA could be considered as a new choice and therefore even introduces new
uncertainty. Finally, researchers should be aware that uncertainty can never be fully quan-
tified. Quantifying uncertainty therefore paradoxically creates a false feeling of certainty,
which can even be artificially induced if important sources of uncertainty are wilfully
ignored.
4.5 Conclusion
Various sources of parameter, model and methodological uncertainty exist when calculat-
ing DALYs for burden of disease assessment. Identifying, quantifying and analysing these
uncertainties should become a standard part of DALY calculations. We recommend PSA
for quantifying parameter uncertainty and scenario analyses for quantifying model and
methodological uncertainties.
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5.1 Introduction
The Disability-Adjusted Life Year or DALY is a summary measure of population health
widely used in disease burden assessment studies and cost-utility analyses (Chapter 1).
DALYs represent the number of healthy life years lost due to a disease or disability, and
do so by incorporating non-fatal and fatal health outcomes, calculated as the years of life
lived with disability (YLD) and the years of life lost due to premature death (YLL), re-
spectively. The formulas for calculating the YLLs and YLDs are presented in Murray [15]
and Murray & Acharya [31], and can easily be incorporated in a spreadsheet, such as
the “DALY calculation template”1 prepared by the World Health Organization (WHO).
This template allows the computation of YLLs and YLDs for both sexes and various age
groups, which are then summarized into a single deterministic DALY measure.
The reliability of the final DALY result depends heavily on the quality of the epidemio-
logical data, which are commonly derived from routine data collection systems, scientific
literature, and expert elicitation. The estimates provided by these data sources include
an inherent level of uncertainty, mainly due to sampling error, diagnostic uncertainty,
and population heterogeneity (as discussed in Chapter 4). To reflect this stochastic
nature, epidemiological parameters are often accompanied by a confidence or credibility
interval, or represented as a probability distribution, rather than being represented by a
single point estimate. Monte Carlo simulations have been suggested as the appropriate
technique to incorporate this uncertainty in the final DALY estimate [95], which can then
be presented as a point estimate with a credibility interval. This interval allows the as-
sessment of the level of uncertainty in the total DALYs, and facilitates a more reliable
comparison of the health impact of different diseases.
To our knowledge, however, there are no standardized tools available for stochastic
DALY calculation. Therefore, we designed a Graphical User Interface (GUI) for calculat-
ing DALYs that allows for the incorporation of input uncertainty and the computation of
a DALY credibility interval through Monte Carlo simulations. This program, the DALY
Calculator, is designed to be used by a variety of users, with different levels of statistical
skills, to allow maximum flexibility, and to promote consistency in the DALY uncertainty
analysis.
1http://www.who.int/entity/healthinfo/bodreferencedalycalculationtemplate.xls
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5.2 Installing and running the DALY Calculator
The DALY Calculator is developed in R, an open-source environment for statistical pro-
gramming and graphics [102]. The use of the DALY Calculator requires the prior installa-
tion of R, which can be freely downloaded from the Comprehensive R Archive Network
(CRAN): http://cran.r-project.org/
The installation procedure under Mac OS X is somewhat more complicated. Two addi-
tional tools need to be installed:
• The X Window System (X11): if this is properly installed, the file X11.app should
appear in the Utilities folder under Applications in the Finder. If not, you can install
it from your Mac OS X installation disc.
• Tcl/Tk for X Windows: this can be installed by downloading and installing tcltk-
8.5.5-x11.dmg from http://cran.r-project.org/bin/macosx/tools/
Linux users may need to download and install the Tktable toolkit, which can be found
through http://packages.ubuntu.com/search?keywords=tk-table. Ubuntu/Debian users
may download and install the toolkit directly by issuing any of the following commands
from Terminal:
sudo apt-get install tk-table
sudo apt-get install libtktable2.10
The DALY package is available on the CRAN repository, and can be installed directly
from the R console, by calling:
install.packages("DALY")
Finally, every time the DALY Calculator has to be used, the DALY package has to be
loaded by typing the following command in the R console:
library(DALY)
This call will load and attach the DALY package, and initiate the main window of the
DALY Calculator (Figure 5.1).
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Figure 5.1: DALY Calculator main window in Ubuntu, Mac OS X 10.6, and Windows 7.
Figure 5.2: DALY Calculator ‘File’ menu. Figure 5.3: DALY Calculator ‘Settings’ menu.
Figure 5.4: DALY Calculator ‘Help’ menu.
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5.3 Getting started with the DALY Calculator
The DALY Calculator is designed to be used in an outcome-based as well as an agent-
based approach. Depending on the approach, YLDs, YLLs, DALYs and incident cases
and deaths can be computed for a combination of up to eight different disease categories
of one outcome, or of up to eight different outcomes of one agent.
According to the original GBD studies, the incidence-based approach was favored over
the prevalence-based approach. The current version of the DALY Calculator is able to
calculate DALYs for a basic incidence-based disease model with well-defined incidence
and/or mortality rates per disease category or outcome.
The default age groups used by the DALY Calculator are the five age groups used by the
GBD 1990 study: 0-4; 5-14; 15-44; 45-59; 60+ [8]. At least one combination of sex and
age group has to be set in order to proceed with the DALY calculation.
To compute YLDs, YLLs, DALYs, incident cases and deaths, five steps have to be fol-
lowed (as illustrated in Figure 5.6 and 5.7). These steps will be explained using one of the
two built-in examples (The burden of Taenia solium cysticercosis in Cameroon; Praet et
al. [81]). Users can load this example by selecting:
Help > Load examples > Neurocysticercosis, Cameroon (Praet et al., 2009)
STEP 1: Set the population table
Clicking the set population button opens the Population window, where the number of
males and females, per age group, can be entered. At least one combination of sex and
age group has to be set.
Figure 5.5: Population of West-Cameroon, stratified by sex and age.
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1 
2 
Figure 5.6: DALY calculation with the DALY Calculator: setting the ‘Population’ table (1)
and the ‘Life Expectancy’ table (2).
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STEP 2: Set the life expectancy table
The default life expectancy table used by the DALY Calculator is the Coale and Demeny
model life-table West, level 26 and 25, which has a life expectancy at birth of 80 for males
and 82.5 for females [15]. However, the user can define his own life expectancy table, by
accessing the Life Expectancy window through the Settings menu:
Settings > Life Expectancy
Praet et al. [81] applied the standard life expectancy table, which is the default life
expectancy table of the DALY Calculator. Therefore, no action is required during this step.
STEP 3: Set the input parameters, per disease category or outcome
After entering the disease and outcome names, the epidemiological data and disability
weights can be entered by clicking the set data button. For every parameter, the user can
specify the distribution by selecting one of following:
• Beta-Pert (mode; min; max)
• Beta (alpha; beta)
• Gamma (shape; rate)
• Normal (mu; sigma)
• Lognormal-geometric (logmean; logsigma)
• Lognormal-arithmetic (mean; sigma)
• Uniform (min; max)
• Fixed
Next, the user has to select the specific level of stratification for every parameter. The
following four stratification levels are available:
• Age and Sex: full stratification
• Age: data is stratified by age group, but not by sex
• Sex: data is stratified by sex, but not by age group
• None: no stratification, data applies to total population
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For calculating the YLDs and incident cases, the following tables have to be completed:
• Incidence: number of new cases per 1,000 persons per year
• Treatment: proportion of patients receiving proper treatment; range [0-1]
• Onset of the disease: age of onset in years
• Duration of the disease: duration in years
• Disability Weight for treated cases: range [0-1]
• Disability Weight for non-treated cases: range [0-1]
For calculating the YLLs and deaths, the following tables have to be completed:
• Mortality: number of deaths per 1,000 persons per year
• Average age at death: age at death in years; based on these values, the DALY Calcu-
lator will compute the corresponding life expectancies according to the specified life
expectancy table.
By default, the distributions of incidence and mortality will be set to Gamma, those of
the proportion treated and the disability weights to Beta, and those of onset, duration
and average age at death to Fixed; the level of stratification for all parameters is set to
full stratification (i.e., Age and Sex).
Figure 5.9 shows the input parameters used for the Neurocysticercosis example.
STEP 4: Set the social values
The default social weighting values applied by the DALY Calculator are uniform age weights
(i.e., no age weighting) and a zero discount rate. However, the user is given the possibility
to define the required set of social values, and to alter these values to assess their influence
on the final result.
Figure 5.8: DALY Calculator main window, with social values set to full age weighting and
a 3% discount rate, as applied by Praet et al. [81].
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Figure 5.9: Epidemiological parameters for the DALY calculation of Neurocysticercosis in
Cameroon, based on Praet et al. [81].
STEP 5: CALCULATE DALYs
Clicking the CALCULATE DALYs button will read the data and compute the YLDs, YLLs,
DALYs and incident cases and deaths per disease category/outcome. By default, the
overall mean, median and a 95% credibility interval of these results will be printed to the
R Console, and a histogram of total DALYs, with corresponding credibility interval, will
be displayed (Figure 5.10).
Figure 5.10: Standard output of the DALY calculation for Taenia solium Neurocysticercosis
in West-Cameroon, based on Praet et al. [81].
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A more detailed output of the DALY calculation can be obtained by changing the out-
put settings in the Options window (Figure 5.11):
Settings > Options
Figure 5.11: ‘Options’ window.
The following settings are possible:
• Age/Sex classes
– Results summed over different age/sex classes (default)
– Results shown per age/sex class
• Outcomes
– Results summed over different outcomes (default)
– Results shown per outcome
• Absolute/Relative
– Absolute values (default)
– Relative values, i.e., per 1000 population
More advanced output, both numerically and graphically, can be obtained by saving the
DALY Calculator output to an R object, and manipulating this object in the R environment
(see Section 5.5 for more details and examples).
5.4 Using the DALY Calculator table widgets
All tables of the DALY Calculator are built using the Tktable toolkit. The navigation
and editing properties of this tabulator toolkit differ from those of common spreadsheet
documents, which may cause confusion. Some clues are therefore useful to get started:
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• Keyboard navigation is only possible through the arrow keys; pressing the RETURN
(ENTER) key will not change focus to the underlying cell, but will append blank
space to the currently active cell.
• To select all values of a column (row), you can click the column (row) header.
Selecting all values in the table is possible by clicking the header in the top-left
corner of the table. Figure 5.12 gives some examples.
• Removing the value of one or more cells can be done by selecting the corresponding
cells and pressing CTRL+X (also on Mac).
• Pasting values into a table (eg, after copying them from a spreadsheet document),
can be done by selecting the top-left cell of the desired range, and pressing CTRL+V
(also on Mac).
Figure 5.12: Selecting columns/rows in DALY Calculator table widgets.
5.5 Handling DALY Calculator output in the R
environment
Instead of clicking the CALCULATE DALYs button in the DALY Calculator main window,
the DALY calculation process may also be invoked by calling the getDALY() function
from the R console. This function initiates the Monte Carlo simulation process, and re-
turns the simulated DALYs, YLDs, YLLs and incident cases and deaths. Of course, this
will only take place if the data have been entered, as outlined before.
The getDALY() function takes two arguments, aw and dr , that specify the age
weighting constant and time discount rate, respectively. If these values are not specified,
they will be taken from the GUI (see Figure 5.8).
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The results of the DALY calculation process can be stored in an object, say x , as
follows:
x <- getDALY()
Since aw and dr were not specified, these values were taken from the GUI. If one
wishes to specify the social weighting values directly from the command-line, the values
from the GUI will be over-ruled. For instance, one could specify to use no age weighting
and a 3% time discount rate as follows:
x <- getDALY(aw = FALSE, dr = 0.03)
5.5.1 Structure of the object returned by getDALY()
The getDALY() function returns an object of class ‘DALY’ , which inherits from class
‘list’ . The returned object is a list containing the following elements:
i For each outcome i , an unnamed list containing simulated
DALYs, YLDs, YLLs and incident cases and deaths, per age/sex
class;
pop A matrix containing the population data;
name The name of the disease.
Each list of simulated results for a certain outcome i contains the following six ele-
ments:
DALY 3-dimensional array of simulated DALYs;
YLD 3-dimensional array of simulated YLDs;
YLL 3-dimensional array of simulated YLLs;
cases 3-dimensional array of simulated incident cases;
deaths 3-dimensional array of simulated deaths;
name The name of the outcome;
input A list containing the simulated samples (arranged in
3-dimensional arrays) from all input distributions.
The three dimensions of DALY , YLD , YLL , cases , deaths and the input elements,
are, respectively, iteration, age group, and sex.
The input element is a list of eight arrays, named as follows:
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inc incidence rate;
trt proportion treated;
ons age at disease onset;
dur disease duration;
DWt disability weight for treated cases;
DWn disability weight for non-treated cases;
mrt mortality rate;
dth age at death.
5.5.2 Methods for objects of class ‘DALY’
Six methods have been made available for the objects of class ‘DALY’ :
print() print results, summed over age/sex classes;
summary() print results, per age/sex class;
aggregate() aggregate simulations by outcome, age/sex, or both;
hist() histogram of total DALYs, YLDs, YLLs, cases or deaths;
plot() plot a stacked barplot of YLLs/YLDs with a DALY error bar;
scatterplot() generate a scatterplot of population versus patient level burden.
In both the print() and summary() methods, the user can specify whether or not
to print the results per outcome (argument outcome ), and whether or not to print the
results relative to the population (i.e., per 1000 population; argument relative ). By
default, outcome and relative are set to FALSE .
The argument digits of both the print() and summary() methods controls the
number of decimal digits to be printed. By default, digits equals 0 . The argument
prob of the print() method sets the range of the printed credibility interval. By de-
fault, prob equals 0.95 .
For example, if one wishes to see the results of the Neurocysticercosis example expressed
relative to the population size, and with 90% credibility intervals, one would call:
print(x, relative = TRUE, prob = 0.90, digits = 2)
##
## DALY Calculator: Neurocysticercosis
##
## Total population: 5065382
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## Mean Median 5% 95%
## DALY 8.91 8.10 3.39 17.23
## YLD 1.37 1.32 0.78 2.11
## YLL 7.55 6.72 2.09 15.82
## cases 3.60 3.60 3.29 3.92
## deaths 0.25 0.22 0.07 0.52
##
## YLD/DALY = 19%
## YLL/DALY = 81%
The hist() method plots a standardized histogram of simulated results. By default,
argument xval is set to "DALY" , argument prob to 0.95 , and argument central
to "mean" . The histogram shown in Figure 5.10 is a result of these default settings.
If one wishes to see a histogram of, say, the number of deaths in the Neurocysticercosis
example, with an indication of the median and a 90% credibility interval, one would call:
hist(x, xval = "deaths", prob = 0.90, central = "median")
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Figure 5.13: Histogram of deaths due to Neurocysticercosis, West Cameroon
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5.5.3 Handling objects of class ‘DALY’
The strength of the implementation of the DALY Calculator is that its results can be di-
rectly manipulated from within the R environment. This allows users to obtain virtually
any possible numerical or graphical output they desire. Of course, this also requires a
more advanced knowledge of the R programming language. Some examples might there-
fore be useful.
Each of the elements of x may be extracted using the [[ operator. Named elements
may also be extracted using the $ operator. For example, we can view the population
matrix of the Neurocysticercosis example as follows:
x[["pop"]] # equivalent to 'x$pop'
## [,1] [,2]
## [1,] 397229 408673
## [2,] 686600 706380
## [3,] 1073342 1104265
## [4,] 210474 216538
## [5,] 129081 132800
Likewise, the simulated DALYs due to epilepsy (i.e., outcome 1 of the Neurocysticercosis
example), may be extracted as follows (note the double indexing):
x[[1]][["DALY"]]
The aggregate() method is a utility function used to sum up simulated results by
outcome, age/sex, or both (controlled by argument by ). This method returns a list of
aggregated DALYs, YLDs, YLLs, incident cases and deaths, as well as the population
matrix and disease name.
aggregate(x, by = "outcome") # aggregate by outcome, sum over age/sex class
aggregate(x, by = "class") # aggregate by age/sex class, sum over outcomes
aggregate(x, by = "total") # sum over outcomes and age/sex classes
As an example, suppose one would like to have a boxplot of total YLDs, YLLs and
DALYs from the Neurocysticercosis example:
y <- aggregate(x, by = "total")
boxplot(y$YLD, y$YLL, y$DALY, names = c("YLD", "YLL", "DALY"))
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Figure 5.14: Boxplot of YLDs, YLLs and DALYs for Neurocysticercosis, West Cameroon
5.6 Sensitivity analysis
Sensitivity analysis (or variable importance analysis) studies how the uncertainty in the
overall DALY estimate can be apportioned to the different sources of uncertainty in the in-
put parameters [103]. These results can therefore help to identify those input parameters
that cause significant uncertainty in the overall DALY estimate and that therefore may be
the focus of further research if one wishes to reduce the uncertainty in the overall estimate.
The sensitivity() function implements a probabilistic global sensitivity analysis
of the overall DALY estimate, in which the analysis is conducted over the full range
of plausible input values (hence global), determined by the specified uncertainty distri-
butions (hence probabilistic). Two general methods are available, i.e., based on (stan-
dardized) regression coefficients ( method = "src" ) or on partial correlation coefficients
( method = "pcc" ). The sensitivity() function is defined as follows:
sensitivity(x, method = c("src", "pcc"), rank = FALSE, mapped = TRUE)
Specifying method = "src" will perform a linear regression-based sensitivity analy-
sis. Here, the simulated overall DALY estimates will be regressed against the simulated
values for the stochastic input parameters (using lm() ). To facilitate comparison, the
independent terms are standardized (using scale() ) such that they are normally dis-
tributed with mean zero and standard deviation one. The resulting regression coefficients
are therefore referred to as standardized regression coefficients.
Argument rank specifies whether the regression should be performed on the actual
values ( rank = FALSE ; default) or on the ranked values ( rank = TRUE ). Rank-based
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regression may be preferred when the relation between output and inputs is non-linear.
R2 values smaller than 0.60 may be indicative of a poor fit of the default linear regression
model.
If mapped = TRUE , the dependent term is not standardized, such that the resulting
mapped regression coefficients correspond to the change in overall DALY given one stan-
dard deviation change in the corresponding input parameter. If mapped = FALSE , the
dependent term is standardized, such that the resulting standardized regression coeffi-
cients correspond to the number of standard deviations change in overall DALY given one
standard deviation change in the corresponding input parameter.
Specifying method = "pcc" will calculate partial correlation coefficients for each of
the input variables. Partial correlation coefficients represent the correlation between two
variables when adjusting for other variables. In the presence of important interactions
between input variables, partial correlation coefficients may be preferred over standard-
ized regression coefficients.
Argument rank specifies whether the correlation should be calculated between the
actual values ( rank = FALSE ; default) or between the ranked values ( rank = TRUE ).
The sensitivity() function returns an object of class ‘DALY sensitivity’ . Both
a print() and plot() method are available for this class, the latter generating a tor-
nado plot of the regression or partial correlation coefficients.
For example, a sensitivity analysis of the Neurocysticercosis model, based on mapped
regression coefficients, could be performed as follows:
sa <- sensitivity(x, method = "src", mapped = TRUE)
## show results of sensitivity analysis
print(sa)
## Mapped standardized regression coefficients:
## Estimate Std. Error t value Pr(>|t|)
## mrt1 21897.942 1.505 14549.977 0 ***
## DWn1.3 1725.126 1.505 1146.392 0 ***
## DWn1.2 901.396 1.505 598.937 0 ***
## DWt1.3 410.693 1.505 272.862 0 ***
## inc1.M.3 284.638 1.505 189.112 0 ***
## inc1.F.3 280.846 1.505 186.619 0 ***
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## DWn1.4 237.095 1.505 157.515 0 ***
## DWt1.2 213.054 1.505 141.567 0 ***
## inc1.F.2 149.741 1.505 99.507 0 ***
## DWn1.1 146.834 1.505 97.586 0 ***
## inc1.M.2 143.994 1.505 95.687 0 ***
## DWn1.5 90.457 1.505 60.115 0 ***
## trt1 -61.807 1.505 -41.077 0 ***
## DWt1.4 54.818 1.505 36.429 2.24e-281 ***
## inc1.M.4 41.145 1.505 27.338 1.4e-161 ***
## inc1.F.4 37.730 1.505 25.069 1.38e-136 ***
## DWt1.1 31.732 1.505 21.087 1.22e-97 ***
## inc1.F.1 25.253 1.505 16.781 8.98e-63 ***
## DWt1.5 23.401 1.505 15.548 3.43e-54 ***
## inc1.M.1 20.817 1.505 13.833 2.54e-43 ***
## inc1.M.5 14.897 1.505 9.899 4.77e-23 ***
## inc1.F.5 13.275 1.505 8.822 1.21e-18 ***
## ---
## Signif. codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1
##
## Adjusted R-squared: 1
## plot tornado graph
plot(sa)
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Figure 5.15: Tornado plot for Neurocysticercosis DALYs, West Cameroon
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From the above results, we learn that the uncertainty in mortality rate has the highest
influence on the overall uncertainty. Indeed, one standard deviation change in mortality
rate would lead to a difference of more than 20,000 DALYs in the overall DALY estimate.
5.7 Scenario analysis
To assess the impact of methodological choices, such as the application of age weighting
or the choice of the discount rate, different scenarios can be run and the results compared.
Likewise, scenario analyses can be performed to assess model uncertainty.
The DALY list() function combines multiple ‘DALY’ objects into an object of class
‘DALY list’ . Methods exist to print the different scenario results and for producing
comparative stacked barplots and scatterplots.
As an example, we will calculate DALYs for the neurocysticercosis example based
on three different social weighting scenarios, i.e., no age weighting or time discounting
(DALY[0;0]), no age weighting but 3% time discounting (DALY[0;0.03]), and age weight-
ing and 3% time discounting (DALY[1;0.03]).
## calculate DALYs under different scenarios
ncc_00 <- getDALY(aw = FALSE, dr = 0)
ncc_03 <- getDALY(aw = FALSE, dr = 0.03)
ncc_13 <- getDALY(aw = TRUE, dr = 0.03)
## save results as 'DALY_list'
ncc <- DALY_list(ncc_00, ncc_03, ncc_13)
## barplot of different scenarios
plot(ncc, names = c("DALY[0;0]", "DALY[0;0.03]", "DALY[1;0.03]"))
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Figure 5.16: Scenario analysis for the Neurocysticercosis DALY calculation, West Cameroon
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5.8 Saving and loading input data
An additional feature of the DALY Calculator is the possibility to save the entered values
for the epidemiological parameters to an .RData image file. This function is available
through:
File > Save DALY data to file. . .
Thus created .RData files can be reloaded into the DALY Calculator by accessing:
File > Load DALY data from file. . .
Alternatively, saving and loading .RData files can be done directly from the R console:
saveDALYdata() # save data to .RData file
readDALYdata() # load data from .RData file
5.9 Current limitations and future work
The current version of the DALY Calculator allows basic DALY calculations and uncer-
tainty analyses, which could be useful for a variety of users. However, certain restrictions
might limit a more advanced performance. The current version of the DALY Calculator is
designed to calculate a basic incidence-based disease model, with well-defined incidence
and mortality rates per disease category or outcome. The incorporation of conditional
probabilities or the calculation of complex disease models is currently not possible. Fur-
thermore, the DALY Calculator only allows the simultaneous assessment of up to eight
health states and up to five age groups. This is sufficient for most diseases or agents, but
could be limiting for certain more complex models. Finally, there are currently only two
DALY calculation examples are built-in.
Efforts are being made to resolve these limitations, and solutions should be provided
in the next major releases of the DALY Calculator. Indeed, a new version of the DALY
Calculator is in development, and has already been used as the basis for the computational
framework of the Foodborne Disease Burden Epidemiology Reference Group, a WHO
workgroup tasked with estimating the global burden of foodborne disease [104].
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6.1 Introduction
Various parasites infecting humans depend on vertebrate animals to complete their life
cycle. Humans most commonly become infected with these zoonotic parasites through
consumption of infected hosts or through fecal-oral contamination. The results of these in-
fections may vary from asymptomatic carriership to long-term morbidity and even death.
Although data are still scarce, it is clear that these parasitic zoonoses (PZs) present
a significant burden for public health, particularly in poor and marginalized commu-
nities [105, 106]. Moreover, PZs can lead to significant economic losses, both directly,
through their adverse effects on human and animal health, and indirectly, through con-
trol measures required in the food production chain [107, 108].
Estimates of the impact of diseases on public health, generally referred to as burden
of disease, may be valuable inputs for decision makers when setting policy priorities and
monitoring intervention programs. In Nepal, it is now recognized that health sector needs
should be prioritized, and that disease burden should be considered as one of the bases for
this prioritization [21]. However, disease burden estimates are not readily available. While
the World Health Organization and the Global Burden of Disease (GBD) initiative have
generated such estimates for Nepal, these were largely based on regional extrapolations,
and, more importantly, included only a limited number of PZs [10, 11]. If disease burden
estimates are to be used for priority setting, an incomplete assessment of the burden of
PZs may lead to a vicious circle of under-recognition, a wrong ranking of priorities and
under-funding for research, prevention and control programs [109].
To address this issue, a disease burden assessment of PZs was conducted in Nepal.
Ideally, the primary data sources for such studies would be official surveillance data and
death registers. In Nepal, however, these data sources have limited value in terms of PZs.
The official passive surveillance system of the Government of Nepal, the Health Man-
agement Information System (HMIS), has been reported to suffer from inconsistencies,
incomplete reporting, and under-reporting from mainly central-level and private hospi-
tals [27, 28]. Active surveillance systems are in place, but only target certain vaccine-
preventable diseases, and not PZs. Death registration is reported to have a completeness
rate of 32% [110]. We therefore opted for a more comprehensive approach, based on a
systematic review of all possible secondary data sources related to PZs in Nepal from 1990
to 2012. This comprehensive review allowed us to identify endemic and possibly endemic
PZs, and, subsequently, to quantify the disease burden of those PZs for which sufficient
quantitative data were available.
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6.2 Materials and Methods
The main objective of this study was to provide a comprehensive overview of the public
health impact of PZs in Nepal. To this end, a step-wise approach was taken:
1. Systematic review of national and international peer-reviewed and grey literature;
2. Qualitative assessment: classification of considered PZs according to (presumed)
endemicity status and data availability; and
3. Quantitative assessment: quantification of health impact of endemic PZs in
terms of the annual number of cases, deaths and Disability-Adjusted Life Years
(DALYs), for the year 2006.
6.2.1 Considered PZs
The twenty PZs considered in this study are listed in Table 6.1. This selection is based
on a recent review of the world-wide socioeconomic burden of PZs [105] and a review of
emerging food-borne parasites [111], as many PZs may be classified as being food-borne.
Seven of the considered PZs also belong to the group of neglected tropical diseases, i.e.,
leishmaniosis, cystic and alveolar echinococcosis, cysticercosis, food-borne trematodosis,
schistosomosis and soil-transmitted helminthosis [112–114].
6.2.2 Systematic review
Direct and indirect evidence on the occurrence of the considered PZs was located through
a systematic search of national and international peer-reviewed and grey literature. Di-
rect evidence was defined as any data on prevalence, incidence or mortality of the PZ in
humans. Indirect evidence was defined as occurrence of the concerned parasite in animal
hosts or in the environment (e.g., water, soil). If no direct or indirect evidence could be
identified from Nepal (further referred to as “local” evidence), recent case reports were
sought from (North) India, Nepal’s largest neighbour with whom it shares an open border
in the west, south and east, and from the Tibet Autonomous Region, which borders Nepal
in the north (Figure 6.1).
For each PZ, we constructed a search phrase consisting of the key word “Nepal” and
any element of a list containing the name of the PZ, possible synonyms, and the name(s)
of the causative parasite(s). Manuscript titles were retrieved through searching PubMed,
Web of Science, WHO Global Health Library, Asia Journals OnLine and MedInd. If
available, the major Nepalese journals were additionally searched through their websites.
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Table 6.1: Parasitic zoonoses considered in the Nepalese burden of disease study (in alpha-
betical order).
Parasitic zoonosis Involved species Transmission route(s)*
Alveolar echinococcosis Echinococcus multilocularis Fecal-oral
Angiostrongylosis Angiostrongylus cantonensis Snail-borne (meat-borne,
fecal-oral)
Anisakidae infections Anisakis spp.,
Pseudoterranova spp.
Fish-borne
Capillariosis Capillaria philippinensis Fish-borne
Capillaria hepatica Meat-borne
Capillaria aerophila Fecal-oral (earthworm-borne)
Cystic echinococcosis Echinococcus granulosus Fecal-oral
Cysticercosis Taenia solium Fecal-oral
Dirofilariosis Dirofilaria spp. Arthropod-borne
Diphyllobothriosis Diphyllobothrium latum Fish-borne
Foodborne trematodoses Fasciola spp.; Fasciolopsis
buski
Plant-borne
Opisthorchis spp.; Clonorchis
sinensis
Fish-borne
Paragonimus spp. Arthropod-borne
Intestinal flukes Various
Gnathostomosis Gnathostoma spp. Amphibian/reptile-borne
Sparganosis Spirometra spp. Amphibian/reptile-borne
Taeniosis Taenia spp. Meat-borne
Toxocarosis Toxocara spp. Fecal-oral (meat-borne)
Toxoplasmosis Toxoplasma gondii Fecal-oral, meat-borne
Trichinellosis Trichinella spp. Meat-borne
Zoonotic intestinal helminth
infections
Ascaris suum; Trichuris spp. Fecal-oral
Ancylostoma spp.;
Strongyloides stercoralis
Fecal-oral, transcutaneous
Zoonotic intestinal protozoal
infections
Giardia duodenalis;
Cryptosporidium spp.;
Blastocystis spp.
Fecal-oral
Sarcocystis spp. Meat-borne
Zoonotic leishmaniosis Leishmania spp. (excluding L.
donovani)
Arthropod-borne
Zoonotic schistosomosis Schistosoma japonicum Water-borne
Zoonotic trypanosomosis Trypanosoma cruzi Arthropod-borne
*Less common transmission routes are shown in parentheses.
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Figure 6.1: Nepal, in red, bordered by India in the south, and China in the north.
In addition, the thesis libraries of Tribhuvan University (Kathmandu, Nepal) and the
Institute of Agriculture and Animal Sciences (Rampur, Chitwan district) were manually
explored to find relevant manuscripts. Dissertations were also collected from the website
of the Veterinary Public Health master course jointly organized by Chiang Mai University
(Thailand) and Freie Universita¨t Berlin (Germany), as this program has a regular intake
of Nepalese students. No dissertations were sought from countries neighbouring Nepal,
as we did not have prior knowledge of masters courses organized in these countries with
a regular intake of Nepalese students.
In a second step, the retrieved titles were screened for eligibility by applying a set of
predefined criteria to the titles and, if possible, to the abstracts and full texts. Only papers
published in 1990 or later were considered eligible, and no restrictions were placed on the
language of publication. For the qualitative assessment, documents were only excluded if
they did not relate to the PZ in question, or if they did not pertain to Nepal or Nepalese
patients. For the quantitative assessment, additional restrictions were put on the year of
publication (between 2000 and 2012), the study setting and population (Nepalese patients
infected in Nepal), and the type of information (quantitative, thus excluding case reports
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and case series). Finally, additional titles were sought for using forward and backward
reference searches (so-called “snowballing”). In the forward reference search, the titles
eligible for the qualitative assessment were entered in Google Scholar to obtain a list of
articles citing the former. The latter were then screened using the same criteria as used
in the initial searches. In the backward reference search, the reference lists of the initially
retrieved eligible documents were hand-searched and the same criteria were applied. The
forward and backward searches were repeated until no more new information could be
retrieved. Figure 6.2 presents a generic flow diagram of this applied search strategy.
QUALITATIVE ASSESSMENT 
 
QUANTITATIVE ASSESSMENT 
 
 
Potentially relevant papers 
identified and screened for retrieval 
 
Studies excluded 
~ not related to Nepal 
~ not related to parasitic zoonoses 
 
Papers to be included in the 
quantitative assessment 
 
Studies excluded 
~ no quantitative data 
 
Additional papers identified 
through "snowballing" 
 
 
Theses to be included in the 
quantitative assessment 
 
Theses to be included in the 
qualitative assessment 
 
Additional papers identified 
through "snowballing" 
 
 
Papers to be included in the 
qualitative assessment 
Figure 6.2: Generic flow diagram of applied search strategy.
Relevant data on study setting, diagnostic methods and study results were extracted
from all eligible articles, and entered in spread sheet documents for further use.
6.2.3 Qualitative assessment
This initial assessment aimed at classifying the considered PZs according to their pre-
sumed endemicity status and data availability. To this end, we defined four categories:
Probably not endemic: there is no direct or indirect local evidence and no direct
evidence from neighbouring countries;
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Potentially endemic: there is no direct or indirect local evidence, but there is direct
evidence from neighbouring countries; or, there is some direct local evidence, but of
questionable nature, thus needing further confirmation;
Probably endemic & non-quantifiable: there is direct or indirect local evidence;
the burden cannot be quantified due to insufficient quantitative data or uncertainty
in zoonotic potential or health effects;
Probably endemic & quantifiable: there is direct or indirect local evidence; the
burden can be quantified.
Additionally, information regarding the zoonotic nature of potentially zoonotic parasites
was considered, with respect to alternative (dominant) anthroponotic transmission.
6.2.4 Quantitative assessment
Where possible, the prevalence of each PZ classified as “probably endemic & quantifi-
able” was modeled using a random effects meta-analysis in a Bayesian framework. In this
model, it is assumed that the number of positive samples xi in each study results from a
binomial distribution with sample size ni and a study-specific true prevalence θi, which is
in its turn the result of an overall true prevalence pi and a random study effect. The study
effect is assumed to be normally distributed with mean zero and variance τ2. The prior
distribution of τ2 is Gamma with scale and shape parameter equal to 1, while a Normal
distribution with mean 0 and precision 0.001 was used as prior for the logit-transformed
true prevalence. Markov chain Monte Carlo methods are used to fit the model.
If data allowed, the health impact of the concerning PZs was also quantified as the
number of incident cases, deaths and DALYs. The DALY metric is a summary measure
of population health, widely used in disease burden assessments and cost-effectiveness
analyses [10, 11]. DALYs represent the overall number of healthy life years lost due to
morbidity and mortality, hereby facilitating comparisons between diseases, and between
countries and regions. Calculation of DALYs was done using the standard formulas, and
implemented in a fully stochastic framework using the DALY Calculator in R (Chapter 5).
We calculated undiscounted and unweighted DALYs, based on the Coale-Demeny model
life table West, as our base case scenario. However, in order to enhance comparability
of our estimates to estimates made by other authors, we performed scenario analyses by
varying the time discount rate from 0% to 3%, by including age weighting, and by using
the life expectancy table developed for the GBD 2010 study [11]. These different scenarios
were denoted by DALY[K; r], with K equal to 0 for unweighted DALYs and equal to 1
for age-weighted DALYs, and with r the time discount rate. For all scenarios, results
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were calculated at the population level (i.e., absolute number of DALYs per year) and
at the individual level (i.e., relative number of DALYs per symptomatic case). Incident
cases, deaths and DALYs were calculated for reference year 2006, i.e., the midpoint of the
eligible publication period, 2000–2012. The total population size for 2006 was calculated
as the mean of the population sizes estimated in the 2001 and 2011 censuses. The age and
sex distribution of the 2006 population was derived from the 2006 Nepal Demographic
and Health Survey [26]. Table 6.2 presents the resulting population sizes used in the
calculations.
Table 6.2: 2006 age and sex specific population sizes used in the calculation of incident cases,
deaths and DALYs.
Age Male Female Total
0-4 1,766,025 1,673,583 3,439,608
5-14 3,655,548 3,556,364 7,211,913
15-44 4,668,234 6,331,723 10,999,957
45-59 1,259,682 1,464,385 2,724,068
60+ 975,636 920,471 1,896,107
All ages 12,325,126 13,946,527 26,271,653
6.2.5 Ethics statement
The data collection activities required for this study were approved by the ethical review
board of the Nepal Health Research Council (Ramshahpath, Kathmandu, Nepal) and of
the Ghent University Hospital (Ghent, Belgium; registration number B670201111932).
6.3 Results
6.3.1 Systematic review
For all twenty considered PZs, we identified 267 unique peer-reviewed documents and
50 unique dissertations. All identified documents were published in English. Table 6.3
summarizes the results of the systematic review for each considered PZ.
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Table 6.3: Retrieved documents (total, retained)
Parasitic zoonosis Total
unique
titles
Retained titles
Qualitative assessment Quantitative assessment
Literature Snowball Thesis Total Literature Snowball Thesis Total
Alveolar echinococcosis 3 1 0 0 1 0 0 0 0
Angiostrongylosis 3 0 0 0 0 0 0 0 0
Anisakidae infections 0 0 0 0 0 0 0 0 0
Capillariosis 7 2 0 4 6 0 0 0 0
Cystic echinococcosis 34 14 1 7 22 0 0 2 2
Cysticercosis 58 46 12 4 62 9 4 3 16
Diphyllobothriosis 1 0 0 3 3 0 0 0 0
Dirofilariosis 4 0 0 0 0 0 0 0 0
Foodborne
trematodoses
22 2 4 5 11 0 0 0 0
Gnathostomosis 3 0 0 1 1 0 0 0 0
Sparganosis 3 1 0 0 1 0 0 0 0
Taeniosis 36 12 8 13 33 6 4 11 21
Toxocarosis 8 3 0 5 8 0 0 0 0
Toxoplasmosis 35 14 4 3 21 5 1 3 9
Trichinellosis 5 4 0 2 6 0 0 0 0
Zoonotic intestinal
helminth infections
154 83 21 27 131 34 12 19 65
Zoonotic intestinal
protozoal infections
114 62 24 23 109 36 12 16 64
Zoonotic leishmaniosis 242 17 1 1 19 0 0 0 0
Zoonotic
schistosomosis
20 3 0 2 5 0 0 0 0
Zoonotic
trypanosomosis
7 0 0 0 0 0 0 0 0
6.3.2 Burden assessment
Table 6.4 presents the results of the qualitative classification of PZs. Out of the twenty
considered PZs, only Anisakidae infections, zoonotic sleeping sickness (trypanosomosis)
and zoonotic schistosomosis were classified as probably not endemic as no direct or indi-
rect evidence was found. Seven PZs were classified as potentially endemic, i.e., alveolar
echinococcosis, angiostrongylosis, capillariosis, dirofilariosis, gnathostomosis, sparganosis
and cutaneous leishmaniosis. The ten remaining PZs were considered probably endemic,
and the burden of three of these, neurocysticercosis, congenital (but not acquired) toxo-
plasmosis and cystic echinococcosis, could be fully quantified in terms of incident cases,
deaths and DALYs.
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Table 6.4: Results of the qualitative assessment (in alphabetical order)
Probably endemic &
quantifiable
Probably endemic &
non-quantifiable
Potentially endemic Probably not
endemic
Cystic echinococcosis Diphyllobothriosis Alveolar echinococcosis Anisakidae infections
Cysticercosis Foodborne
trematodoses
Angiostrongylosis Zoonotic
schistosomosis
Toxoplasmosis Taeniosis* Capillariosis Zoonotic
trypanosomosis
Toxocarosis Dirofilariosis
Trichinellosis Gnathostomosis
Zoonotic intestinal
helminth infections*
Sparganosis
Zoonotic intestinal
protozoal infections*
Zoonotic leishmaniosis
* For these parasitic zoonoses, prevalence estimates were available
Potentially endemic parasitic zoonoses
No local evidence could be found for alveolar echinococcosis, angiostrongylosis, capillar-
iosis, dirofilariosis, gnathostomosis, or sparganosis. However, recent case reports of these
diseases in India indicate that these might be, or become, endemic in Nepal as well.
Furthermore, some local evidence has been reported on zoonotic leishmaniosis, but this
information remains unconfirmed. If any of these potentially endemic PZs are indeed
endemic to Nepal, their burden is probably limited to a few sporadic cases.
So far, no cases of alveolar echinococcosis have been reported from Nepal, although a
case of alveolar echinococcosis in a monk having traveled to Nepal, India, and Singapore
has been reported [115]. However, given the considerable burden of alveolar echinococco-
sis in Tibetan communities [116], and the presence of putative cases from India [117–119],
there are likely to be some cases in Nepal as well [120].
Human angiostrongylosis, capillariosis, dirofilariosis, gnathostomosis and sparganosis
result from accidental infection with parasites that mainly have rodents, canines or fe-
lines as definitive hosts. The latter hosts are common in Nepal, and Capillaria eggs
have already been identified in dog, cat and monkey stool samples and environmental
samples [121–126], but it is unclear whether these were C. aerophila, or the clinically
more important C. hepatica and C. philippinensis, which cause hepatic and intestinal
capillariosis, respectively. Furthermore, Spirometra has been identified in stray dog stool
samples from Kathmandu Valley [125], and Gewali [122] apparently found Gnathostoma
eggs in water samples from Kathmandu. Human cases of these five PZs have not yet
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been reported from Nepal, but sporadic cases have been reported from India. Cases
of eosinophilic meningitis due to Angiostrongylus cantonensis have been reported mainly
from the southern Indian states [127, 128]. Only few cases of human intestinal and hepatic
capillariosis have been reported from India so far [129, 130]. Ocular and subcutaneous
manifestations of human dirofilariosis due to Dirofilaria immitis and Dirofilaria repens
have been reported from southern states of India, but there have also been cases from the
northern state of Punjab [131, 132]. Barua et al. [133] reported a case of Gnathostoma
spinigerum in a patient from the northeastern Indian state of Meghalaya, while Mukherjee
et al. [134] presented a case of cutaneous gnathostomosis in a female from the northeastern
Indian state of Manipur. Some sparganosis case reports from India have been published,
including cerebral [135], hepatic [136] and visceral manifestations, the latter in a patient
from Uttar Pradesh [137].
It is widely recognized that Nepal is endemic for Leishmania donovani, the causative
agent of anthroponotic visceral leishmaniosis (AVL), locally known as kala-azar [138–
140]. Although some studies have hinted at a possible zoonotic transmission route of L.
donovani [141–143], we considered kala-azar as a purely anthroponotic parasitic disease,
and excluded it from the current study. In addition to AVL, however, several reports have
presented cases of cutaneous leishmaniosis [144–149]. Although most of these cases have
been imported, mostly from the Middle East, one report mentions a case of cutaneous
leishmaniosis caused by Leishmania major in a woman not known to have lived outside
Nepal [150–152]. The presence of Phlebotomus papatasi, a possible vector of L. major and
L. infantum [141, 153–157], further suggests that Nepal might be (or become) endemic
for zoonotic leishmaniosis [158].
Probably endemic parasitic zoonoses
Trichinellosis has been confirmed in pigs, but never in humans in Nepal. Serological
and/or coprological evidence of human infections with Toxocara, Diphyllobothrium, food-
borne trematodes (FBT), and Taenia exists, but the population impact of these PZs is
probably too low to quantify, although certain groups might be at high risk. Although
patent infections with intestinal helminths and protozoa are still very common, the health
impact of zoonotic intestinal helminths and protozoa could not be assessed, due to uncer-
tainty of zoonotic potential and health effects. On the other hand, the health impact of
cysticercosis, toxoplasmosis and cystic echinococcosis was deemed quantifiable.
Trichinella infection has been serologically confirmed in pigs from Kathmandu [159,
160], although Karn et al. [161] could not find seropositives in a sample of 344 pigs
slaughtered in five districts of the Central Development Region of Nepal (including Kath-
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mandu). Larvae have so far not yet been found on digestion. No human cases have been
reported from Nepal, although Joshi et al. [159] mention the undocumented occurrence of
sporadic cases of human trichinellosis reported from medical hospitals, and a trichinellosis
outbreak has been documented from the north Indian state of Uttarakhand [162].
In a serological ELISA study, a high proportion of Nepalese people (∼80%) appeared
positive for Toxocara infection [163]. Recently, two children with eosinophilia were sero-
diagnosed with toxocarosis [164]. Furthermore, Toxocara spp. have been identified from
dogs from Kathmandu [125, 165, 166], cats from Nawalparasi and Chitwan [124], and
water samples from Kathmandu [122, 123].
Diphyllobothrium has been found in dog stool samples from Kathmandu [165] and in the
intestine of common carp fingerlings from a fish farm near Kathmandu [167]. Thapa [168]
reports finding Diphyllobothrium eggs in the stools of 18/62 (29.0%) and 2/90 (2.2%)
people of the Bote and Darai ethnic communities, respectively. Both are marginalized
communities from Chitwan, and mainly depend on agriculture and fishing.
Some Nepali studies have reported trematode eggs in human and animal stools. Eggs
of Fasciola spp. have been reported from buffaloes in a number of studies [169–173]. In
community-based studies conducted in Kavre and Chitwan, Fasciola spp. eggs were re-
ported in human stools [174, 175]. In a study of diarrheal samples from Kathmandu, eggs
resembling those of Clonorchis sinensis or Opisthorchis spp. were found [176, 177]. How-
ever, as identification was based on visual identification only, confirmation is not certain.
Three out of 84 children with eosinophilia presenting at a university hospital in Kavre
were serologically positive for fasciolosis [164], while in another case series on eosinophilia
in children, paragonimosis was suggested as a possible cause, given that a significant pro-
portion of patients had the habit of eating undercooked fresh water crab meat [178]. In
India, human cases of Fasciolopsis buski have been described from the Nepal bordering
states of Bihar [179, 180] and Uttar Pradesh [181].
Taeniosis, due to Taenia solium, Taenia saginata or Taenia asiatica, is commonly re-
ported in Nepal. Different studies indicate low taeniosis prevalences in the general public
and in clinical samples (<2%), although some papers hint at high prevalences in certain
ethnic groups (10–50%). Higher taeniosis prevalence in certain groups is possible, as dis-
cussed by Prasad et al. [182] and Devleesschauwer et al. [183], although estimates of up to
50% are somewhat doubtful. Molecular studies have identified T. asiatica and T. saginata
as causes of taeniosis [183, 184], although it is to be expected that T. solium also causes
taeniosis in Nepal, given its presence in animal intermediate hosts [185]. Apart from rare
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complications such as gastrointestinal obstruction or inflammation, the health impact of
taeniosis is minimal. So far, there has only been one report describing such complications
in a Nepalese patient [186]. As neither the national nor the international literature give
a clear view of the probability of developing such complications, it was decided that the
health impact could not be quantified.
A large number of studies have assessed the prevalence of intestinal helminths and
protozoa in Nepal (Table 6.5). Community-based studies mainly targeted school chil-
dren, while hospital-based studies were mostly set in large urban referral hospitals. Fewer
studies looked at intestinal helminthic and protozoal infestations in HIV-AIDS patients.
However, a meaningful quantification of the public health impact of zoonotic intestinal
helminths and protozoa was deemed impossible, due to the uncertainty regarding the ex-
tent to which these infections are truly zoonotic and the uncertainty regarding the health
effects of zoonotic species [105]. Indeed, the limited available data suggest that intesti-
nal helminth infections are mainly due to anthroponotic species. In the large study on
genetic influences of helminth susceptibility in the Jirel population of Jiri, Dolakha, only
Ascaris lumbricoides was reported [187, 188]. Fecal cultures to identify hookworm lar-
vae so far only revealed the anthroponotic hookworm species Ancylostoma duodenale and
Necator americanus [189, 190]. The zoonotic relevance of intestinal protozoa remains less
clear, even though genetic characterization of Giardia and Cryptosporidium from Nepal
has been performed [191–194]. The zoonotic potential of Blastocystis appears to be best
studied [195–197], yet there is large uncertainty about the prevalence of human infection
given the limited number of studies, as well as substantial doubt regarding its pathogenic
nature [198].
Human cysticercosis in Nepalese people has been described since the early 1990s, mainly
through reports of patients with neurocysticercosis (NCC) [199–209], ocular cysticerco-
sis [210–214] and muscular and soft tissue cysticercosis [215–223]. Its public health impact
however did not receive full attention until the 2000s. Hospital-based studies indicate NCC
prevalences in seizure patients ranging from 7% to 73%. The majority of these studies ap-
plied neuro-imaging. Two studies report the prevalence of NCC in hydrocephalus patients,
indicating a prevalence of 1–2% [224, 225], while a recent study indicates NCC prevalence
of ∼5% in patients with chronic headache [226]. A case series of three Nepalese intraven-
tricular NCC patients molecularly identified the removed lesions as T. solium [227].
The majority of population-based studies on Toxoplasma gondii seroprevalence are
from the 1990s [228–232], apart from two recent studies [233, 234]. T. gondii seropreva-
lence has also been studied in women with bad obstetric history [235–238], patients with
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HIV/AIDS [237, 239–242], ocular disorders [237] and hydrocephalus [224]. Apart from
a recent case description [243], however, there appears to be no direct evidence on the
impact of congenital toxoplasmosis, which is likely to represent the highest population
burden [105]. As a result, it is only possible to obtain an indirect view of the impact of
congenital toxoplasmosis in Nepal through population-based seroprevalence data.
Cystic echinococcosis has traditionally mostly been studied in livestock [125, 244–249].
The few data in dogs indicate higher prevalence in areas where livestock is slaugh-
tered [247, 250]. Since the 2000s, various case reports have been published on human
hydatidosis [251–259]. Hospital register studies for cystic echinococcosis cases have found
low incidences [245, 260, 261]. So far, genotyping studies have revealed the presence of
G1, the sheep strain in humans [262], dogs and livestock [247, 263, 264], G5 (cattle strain)
in livestock [263] and G6 (camel strain) in humans [263].
Quantitative assessment
For intestinal infestations with Taenia spp., helminths and protozoa, we were able to esti-
mate prevalence based on a random effects meta-analysis (Table 6.5). For NCC, congenital
toxoplasmosis and cystic echinococcosis we could estimate the number of incident cases,
deaths and DALYs (Table 6.6). Figure 6.3 visualizes the estimated burden at population
and individual level, taking into account the uncertainty resulting from the parameter
uncertainties, as suggested by Havelaar et al. [55]. Congenital toxoplasmosis has both a
high population and patient burden, while NCC is relatively less important at the patient
level, but equally important at the population level. Cystic echinococcosis appears less
important at both levels.
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Table 6.5: Quantitative assessment: Occurrence of intestinal parasites
Intestinal parasite Datasets Estimated prevalence (%)
Mean 95% Range* Distribution
Community-based studies
Taenia spp. 15 3.4 0.7–8.1 Beta(2.977, 84.058)
Ascaris spp. 37 15.6 10.6–21.4 Beta(26.936, 145.189)
Trichuris spp. 36 11.2 6.4–17.1 Beta(14.545, 115.807)
Hookworm 35 10.4 5.9–15.9 Beta(14.476, 125.337)
Giardia spp. 28 8.9 6.2–12.0 Beta(32.089, 330.444)
Cryptosporidium spp. 12 0.6 0.2–1.4 Beta(4.165, 641.569)
Blastocystis hominis 5 6.9 1.5–15.7 Beta(3.137, 42.457)
Hospital-based studies
Taenia spp. 8 0.5 0.1–1.0 Beta(4.575, 977.996)
Ascaris spp. 25 3.4 1.8–5.5 Beta(12.621, 353.634)
Trichuris spp. 25 1.0 0.4–2.0 Beta(5.588, 550.789)
Hookworm 25 1.5 0.7–2.7 Beta(8.954, 577.751)
Giardia spp. 28 5.5 3.8–7.6 Beta(29.778, 507.152)
Cryptosporidium spp. 17 1.7 0.6–3.3 Beta(6.077, 352.688)
Blastocystis hominis 7 1.2 0.0–4.5 Beta(0.948, 77.444)
HIV-AIDS patients
Ascaris spp. 4 2.1 0.0–9.2 Beta(0.671, 30.91)
Trichuris spp. 4 4.3 0.1–15.5 Beta(0.935, 21.065)
Hookworm 4 3.1 0.0–12.3 Beta(0.79, 24.688)
Giardia spp. 5 5.6 1.7–11.6 Beta(4.32, 73.437)
Cryptosporidium spp. 8 6.4 2.7–11.7 Beta(7.069, 102.905)
Blastocystis hominis 3 2.8 0.1–9.4 Beta(1.157, 40.646)
*Defined as the 2.5th and 97.5th percentile of the concerned distribution
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Table 6.6: Quantitative assessment: Disease impact
Metric* Neurocysticercosis Congenital
toxoplasmosis
Cystic
echinococcosis
Total
Incident cases
(95%CrI)
— 1396 (1058–1780) 145 (114–179) —
Incident symptomatic
cases** (95%CrI)
10,618 (3304–22,296) 626 (473–813) 145 (114–179) 11,389
(4083–23,045)
Deaths (95%CrI) 163 (39–378) 60 (27–105) 3 (0–7) 225 (93–442)
DALY[0;0] (95%CrI) 14,268 (5450–27,694) 9255 (6135–13,292) 251 (105–458) 23,773
(14,094–37,719)
DALY[0;0] /1000
(95%CrI)
0.543 (0.207–1.054) 0.352 (0.234–0.506) 0.010 (0.004–0.017) 0.905
(0.536–1.436)
DALY[0;0]
/symptomatic case
(95%CrI)
1.581 (0.576–4.047) 14.934
(10.128–21.796)
1.741 (0.737–3.243) —
DALY[1;0.03]
(95%CrI)
10,924 (4270–21,301) 3964 (2648–5653) 204 (116–323) 15,092
(8215–25,546)
DALY[0;0.03]
(95%CrI)
8916 (3569–17043) 3553 (2359–5098) 174 (96–277) 12,642
(7046–20,791)
DALY[0;0][GBD2010
LE] (95%CrI)
14,994 (5668–29,273) 9673 (6347–14,017) 263 (106–486) 24,930
(14,706–39,702)
*Scenarios are denoted as DALY[age weighting constant; discount rate]; CrI: Credibility Interval;
GBD2010 LE: Global Burden of Disease 2010 Life Expectancy table
**Incident symptomatic cases are the sum of all clinical manifestations across all incident cases
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Figure 6.3: Population-level (DALY[0;0] per year) versus individual-level burden (DALY[0;0]
per symptomatic case) in Nepal, 2006. The scatterplots represent 1000 random
samples from each distribution, with the black symbol representing the centroid;
both axes are on a log10 scale.
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6.4 Discussion
As disease burden estimates are of increasing importance for policy making and evalua-
tion, the need for such estimates becomes eminent. In the late 1990s, the World Bank
commissioned a comprehensive analysis of health care delivery in Nepal. Several recom-
mendations were made for the further development of the Nepalese health sector, one
of which was the establishment of priorities [20]. These recommendations were carried
forward in the development of the Nepal Health Sector Programmes (NHSP), short-term
strategic frameworks for the further development of the health sector. Since then, disease
burden is recognized as one of the bases for setting program priorities [21]. However, when
routine surveillance systems are performing poorly and baseline epidemiological studies
are rare, these estimates are not readily available ([265]; Chapter 1). In this paper, we
present the first comprehensive systematic review of the burden of PZs in Nepal. Infor-
mation was sought from the international and national peer-reviewed scientific literature,
and an important source of information was found in dissertations. The information found
allowed qualitative assessment of the twenty PZs considered. However, quantitative esti-
mates of prevalence or disease burden were possible for only a few.
Nepal is considered endemic for at least ten PZs, and might be endemic for seven
others. Most of these diseases probably only have a small public health impact. How-
ever, NCC and congenital toxoplasmosis are likely to impose an important burden to
public health. Indeed, if we compare with the three “major” infectious diseases, we see
that the estimated burden due to major clinical manifestations of three PZs, with in
total 0.57 DALY[1;0.03] per 1000 people, is higher than that of the WHO 2004 GBD
estimate for malaria (0.05 DALY[1;0.03] per 1000), comparable to that for HIV/AIDS
(0.74 DALY[1;0.03] per 1000), but substantially lower than that for tuberculosis (5.45
DALY[1;0.03] per 1000) [10]. These comparisons suggest that greater attention for PZs
in Nepal is warranted. Toxoplasmosis is for instance not reported in any official Nepalese
data collection system, and cysticercosis and toxoplasmosis were not considered in the
WHO 2004 GBD update [10]. As a result, the incidence of congenital toxoplasmosis re-
mains a critical data gap, and considerable uncertainties remain regarding the epilepsy
prevalence and proportion of NCC-associated epilepsy. Data on the zoonotic potential
of intestinal helminths and protozoa and their health effects are lacking, although these
infections may represent a considerable additional health burden.
In our study, certain methodological choices were made with as a consequence certain
limitations. First, instead of applying strict inclusion/exclusion criteria, we aimed at
collecting as much relevant information as possible. Inherently, this led to large hetero-
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geneity in the collected quantitative data. As a result, our burden estimates have large
uncertainty intervals, making it for instance impossible to statistically distinguish the
burden of NCC and congenital toxoplasmosis. For congenital toxoplasmosis, as no direct
evidence was available, we estimated the incidence based on a single age-specific sero-
prevalence study. Clearly, this puts an important constraint on the representativeness
of our resulting burden estimate. Direct evidence on the incidence of congenital toxo-
plasmosis (e.g., through serological studies on newborns), preferably obtained through a
multi-center study, is therefore needed to confirm our burden estimate.
Second, uncertainty was introduced by the selection and valuation of the clinical out-
comes for the three diseases. We based our disease models on published studies [64,
80, 81, 266], but note that other authors applied alternative ones. For instance, Bhat-
tarai et al. [85] also included severe headaches in their assessment of the burden of NCC
in Mexico, whereas this was deemed infeasible in our study. Likewise, the disability
weights assigned to the different included clinical outcomes were derived from earlier
studies [64, 80, 81, 266], in order to enhance comparability with those studies. Neverthe-
less, other studies, including the GBD studies, are less transparent about their applied
disease models and disability weights, impeding unambiguous comparisons. For instance,
the GBD 2010 study estimated the number of DALY[0;0] in Nepal to be 667 [141–2073]
for “echinococcosis” and 4220 [2786–6022] for cysticercosis [11]. Given a lack of knowledge
on the disease models, disability weights and data behind these estimates, it is difficult
to assess the reason for any differences or similarities with our estimates. Toxoplasmosis
and other PZs appear to be absent from the GBD 2010 study.
Third, subjective methodological choices regarding the calculation of DALYs may lead
to further uncertainty. We tried to deal with this source of uncertainty by calculating
DALYs under different common sets of normative assumptions, i.e., no discounting and
age weighting, 3% time discounting and no age weighting, 3% time discounting and age
weighting; and by calculating DALYs based on both the Coale-Demeny model life table
West and the new GBD 2010 life expectancy table. As expected, time discounting led to
smaller burden estimates. The difference between both life tables was minimal.
In addition, this study focused on the population burden of PZs. Some PZs, however,
might have an important individual burden, even though their population burden is neg-
ligible or small. Likewise, the burden suffered by specific sub-populations (e.g., caste or
ethnic groups), might be much higher than average population burden [183].
Finally, due to a lack of time and resources, we had to place restrictions on the nature
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of the diseases to be studied, and on the nature of the burden estimates to be generated.
Indeed, this study only focused on the burden of parasitic zoonoses. However, as means
for interventions are poor, future integrated control could be packaged by, for instance,
simultaneously controlling cystic echinococcosis, brucellosis and rabies. This analysis
should therefore be extended to the burden of bacterial and viral zoonoses in Nepal. By
quantifying the burden in terms of incidence, mortality and DALYs, we also focused on
the health impact of the concerned diseases. Some PZs might have an important economic
impact, for example in terms of livestock health, or might reduce psycho-social wellbeing
in a way not captured by the applied metrics. Truly evidence-informed priority setting
and decision making should take into account all these aspects of disease burden, implying
that our estimates should be complemented by others.
Despite these limitations, this study has identified the most important PZs for Nepal, as
far as existing data allowed. The quantitative estimates of disease burden for three of these
diseases suggest that PZs deserve greater attention and more intensive surveillance. As
population and disease transmission dynamics change over time, disease burden changes
dynamically as well. Therefore, the presented results should be updated regularly, and
this exercise should be extended to other groups of neglected diseases or even to a full
national burden of disease study. We therefore hope that this study will stimulate further
research, so that the overall human health burden in Nepal can be better characterized.
In the long term, however, continued efforts to improve surveillance and database system
at the local level should enable truly monitoring of disease burden over time.
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7.1 Introduction
Rabies is a neglected zoonotic disease caused by an RNA virus of the family Rhabdoviri-
dae, genus Lyssavirus. All mammals can be infected with the rabies virus, but dogs and
dog bites are the most important source of human rabies. Although the necessary evi-
dence and tools are in place to control and eliminate rabies, the virus still has a worldwide
distribution and is causing a significant health and economic burden to mainly developing
countries in Africa and Asia [84].
Rabies is a vaccine-preventable disease. Modern cell culture-based and embryonated
egg-based anti-rabies vaccines (ARV) have proven to be safe and effective in preventing
rabies [267]. Earlier nerve tissue ARV could induce severe adverse reactions and were
less immunogenic. As a result, the production and use of nerve tissue ARV has been
discouraged by the World Health Organization (WHO) since 1984 [268]. Pre-exposure
prophylaxis (PrEP) is recommended to individuals coming in close contact with (speci-
mens of) rabid animals, such as laboratory technicians and veterinarians. Once exposed
to a rabid animal, timely post-exposure prophylaxis (PEP) can be lifesaving. The WHO-
recommended PEP protocol consists of immediate primary wound management, accom-
panied by a recommended course of ARV and, for high risk exposures, administration of
rabies immunoglobulin (RIG). Intradermal administration of ARV is recommended over
intramuscular administration, as it reduces the volume used and thus the direct cost of
the vaccine by 60-80%, without compromising on safety or immunogenicity [268].
Although proper implementation of PrEP and PEP can significantly reduce the bur-
den of human rabies, it is not a sustainable approach for controlling rabies. Indeed,
prophylaxis alone does not reduce the rabies transmission and can induce an unbearable
economic burden on households, communities and governments. The Partners for Rabies
Prevention, an international group of agencies and experts involved in rabies, developed
a blueprint for rabies prevention and control [269]. The main intervention strategy in
the dog rabies control blueprint is mass dog vaccination, possibly complemented with
dog population management measures. However, proper planning and evaluation are
equally crucial components of the blueprint. In the planning phase, information should
be gathered on the local rabies epidemiology and the extent of the dog population. Also,
awareness should be created and support elicited from both the local population and the
relevant governmental agencies. Once a programme is in place, the change in epidemio-
logical, economic and social impact of the disease needs to be monitored to evaluate the
effectiveness of the programme. Reliable baseline data and effective rabies surveillance
are inevitable to accomplish this goal.
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This chapter focuses on the rabies situation in Nepal. Landlocked between India and
China, Nepal has a surface of 147,000 km2 and a population of approximately 29 million.
Geographically the country can be divided in three ecological belts, i.e., the northern
Himalayas, the central hills, and the southern Terai plains. Due to a concurrent history
and an open border, Nepal has similar socioeconomic conditions as India, the country with
the largest rabies burden worldwide [84]. Nevertheless, little is known about the actual
status of rabies in Nepal. This review summarizes current knowledge on epidemiology,
impact and control of rabies in Nepal, and ends with recommendations for a way forward.
7.2 Materials and methods
We used a variety of sources to search for information on rabies in Nepal. We performed
a systematic review of scientific literature indexed in PubMed, Web of Knowledge and
Nepal Journals Online1, complemented by manual searches of main Nepalese journals, the
Journal of the Association for Prevention and Control of Rabies in India2 and the confer-
ence proceedings of the Rabies in Asia (RIA) foundation3. We searched for the following
key words: (“rabies” OR “rabid” OR “dog”) AND “nepal”, and excluded items that did
not pertain to rabies in Nepal. Further grey literature was collected through browsing
the websites of the WHO and the National Zoonoses and Food Hygiene Research Centre
(NZFHRC). We also searched Google and Google Scholar for additional documents, but
acknowledge that these searches are not replicable, due to the continuous updating of the
Google databases and the user-specific ranking of database items.
Additionally, we reviewed websites and documents from relevant government agencies.
Rabies surveillance in Nepal is passive and based on a decentralized data collection sys-
tem. The Veterinary Epidemiology Centre (VEC), resorting under the Directorate of
Animal Health (DAH), Department of Livestock Services (DLS), Ministry of Agricultural
Development, is the national focal point for animal disease surveillance, including rabies.
Passive surveillance for human rabies is comprised in the Health Management Informa-
tion System (HMIS), managed by the Department of Health Services (DoHS), Ministry
of Health and Population. The Zoonotic Disease Sub-section of the DoHS Epidemiology
and Disease Control Division (EDCD) is responsible for prevention and control of rabies
and other zoonotic diseases.
1http://www.nepjol.info/
2http://apcrijournal.org/
3http://www.rabiesinasia.org/riacon.html
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Finally, we searched news items on rabies in Nepal from the archives of The Himalayan
Times, a large English-language Nepalese daily, and ProMED, a global electronic reporting
system for outbreaks of infectious and other diseases. We acknowledge that these data
sources do not provide reliable quantitative information, but believe that they are useful
sources of qualitative information on the rabies situation in Nepal.
7.3 Results
7.3.1 Data sources
Little original research has been conducted on the epidemiology and impact of rabies in
Nepal. From the systematic review, we retained a total of 22 documents. The further
online searches revealed another 38 documents.
We obtained a dataset from the VEC containing reported data for the period 2000–
2009. The same dataset has been, in total or partly, discussed by Gongal [270] and Karki
& Thakuri [271]. The VEC receives a monthly Animal Disease Epidemiological Report
in a specified format from all 75 District Livestock Service Offices (DLSO). Each DLSO,
in its turn, receives animal health and disease data from the animal health technicians
working in the various Village Development Committees, the lowest administrative level
in the Nepalese system [270]. Further information on rabies in Nepal was available from
two DAH Annual Technical Reports [272, 273].
Since 1994, the DoHS publishes Annual Reports which analyse the performance of dif-
ferent programmes and present information collected by the HMIS4. In fiscal year 2012/13,
all 75 District (Public) Health Offices, 82.9% of public hospitals, 95.4% of Primary Health
Care Centres, 98.4% of Health Posts, 96.3% of Sub Health Posts reported to HMIS [274].
A total of 441 NGO and 669 private health institutions also reported to HMIS that year.
The Annual Report contains information on the number of dog bites and other animal
bites, by district, reported to the concerned health centres. It also contains hospital inpa-
tient data on rabies morbidity and mortality, based on the ICD codes A82 (Rabies) and
A82.8 (Rabies, unspecified). We obtained DoHS Annual Reports for fiscal years 2001/02
to 2012/13, the latest issue available.
4http://dohs.gov.np/
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7.3.2 Epidemiology
Rabies in Nepal occurs in two interrelated epidemiological cycles: an urban cycle involving
domesticated dogs and a sylvatic cycle involving wildlife [275]. The urban cycle is the pre-
dominant source of human rabies, with more than 96% of rabies patients reported during
1991–2000 showing a history of rabid dog exposure [276]. Nevertheless, overlap between
both cycles does occur. Indeed, spill-over between cycles has recently been demonstrated
by the isolation of a virus from a human rabies case that showed 100% identity over the
studied region to viruses previously isolated from two dogs and a mongoose (family Her-
pestidae) in Nepal [277].
The urban cycle is maintained by the stray and community dog population, with spill-
overs to pet dogs adding to the human rabies burden. There is little current information
on the extent of the stray dog population in Nepal. According to a dog census carried out
by the NZFHRC in 1998, there would be nearly 2 million dogs in Nepal [278]. However,
most other surveys have been conducted in the Kathmandu Valley of Nepal, comprising
the Kathmandu, Bhaktapur and Lalitpur districts. In 1989, Bo¨gel & Joshi [279] estimated
a dog population of 12,500 in Lalitpur city, or 700 per km2. In October 1997, a much
higher stray dog density of 2,930 dogs per km2 was established in Kathmandu [280]. With
an area of just over 50 km2, this would correspond to a total of nearly 150,000 stray dogs.
More recently, animal welfare organizations have undertaken several dog population sur-
veys in the Kathmandu Valley. Within the Ring Road area, the estimated dog population
was 31,000 in 2006, dropping to 22,500 in 2010 and 22,300 in 2012 [281, 282].
One cause of this problematic size is the religious adoration of the dog [279]. The cul-
mination of dog worship takes place on Kukur Tihar, the second day of Tihar, the festival
of lights, on which dogs are worshipped with garlands, tika and food. However, more
important factors for the sustenance of the stray dog population are probably the bad
garbage policy and open slaughter facilities, especially in the Kathmandu Valley [283].
The decline in the vulture population since the 1990s also implied the loss of a competitor
for food [284]. Finally, the rapid urbanization and the growth of slum areas further create
favourable conditions for the sustenance of stray dog populations [285, 286].
The sylvatic cycle is maintained by wild carnivores living in forest zones, national parks,
or wildlife reserves, such as mongooses (family Herpestidae), jackals (Canis aureus), foxes
(Vulpes spp.), wolves (Canis lupus) and tigers (Panthera tigris) [276]. In Nepal, the
direct importance of this cycle is thought to be less important, although it probably has a
significant indirect importance as continuous source of infection for the urban cycle [275,
277].
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Rhesus macaques (Macaca mulatta) are abundant in certain temple areas inside and
outside of the Kathmandu Valley. Although these temple monkeys can become infected
through the urban and sylvatic cycle, their role in rabies transmission is unclear. Never-
theless, monkey bites or scratches are reported to occur frequently in tourists and expats
staying in Kathmandu [287, 288], and in India, a rhesus macaque is believed to have
transmitted rabies to a 10-year-old Australian boy [287, 289]. Furthermore, monkeys are
occasionally reported to menace the local population, although it is not always clear if
this is due to rabies infection.
The risk of rabies infection is believed to be highest in the southern Terai plains, which
are densely populated agricultural areas and contain various wildlife areas [270, 276].
Nevertheless, animal and human rabies is reported from nearly all 75 districts of the
country. Figure 7.1 shows the distribution of rabies outbreaks reported to the VEC
during 2000–2009. The districts with the highest number of outbreaks were Surkhet (193),
Nawalparasi (189), Makwanpur (140) and Jhapa (139). No outbreaks were reported from
six mountain districts (Bajhang, Bajura, Manang, Mugu, Mustang, Sindhupalchowk) and
three hill districts (Gulmi, Myagdi, Ramechap).
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Figure 7.1: Number of rabies outbreaks reported during 2000–2009 to the Veterinary Epi-
demiology Center of the Directorate of Animal Health, Department of Livestock
Services, Ministry of Agricultural Development.
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7.3.3 Impact
Animal rabies
Thakuri et al. [290] observed 34 rabies cases in cattle during 1985–1990 at the veterinary
hospitals of four hill districts in Eastern Nepal. The only recent epidemiological data on
animal rabies in Nepal stem from the VEC. Table 7.1 shows the number of affected, dead,
vaccinated and treated animals as reported to the VEC during 2000–2009. During that
period, a total of 1692 animals were reported dead and 88,002 vaccinated. Cattle and buf-
falo appeared to be the most affected livestock species. However, the reporting of animal
rabies cases is probably dependent on the economic value of the affected species [270].
Table 7.1: Animal rabies cases reported during 2000–2009 to the Veterinary Epidemiology
Center of the Directorate of Animal Health, Department of Livestock Services,
Ministry of Agricultural Development.
Species Affected Dead Vaccinated Treated
Dog 3,927 551 79,528 837
Cat 0 0 2 0
Cattle 1,187 600 3,266 542
Buffalo 681 377 2,222 149
Goat 440 128 1,192 158
Sheep 45 5 1,210 34
Horse 20 8 209 2
Pig 62 23 205 7
Molecular identification of animal rabies virus has identified both the Indian subconti-
nent lineage and the Arctic lineage to occur in animals in Nepal [291].
Human rabies
Epidemiological data on human rabies are available from the Annual Reports of the DoHS.
The total number of reported dog bites showed a steady increase, from 15,000 in 2001 to
35,000 in 2012. Figure 7.2 shows the apparent distribution of dog bites in Nepal. Nearly
5% of all dog bites occurred in the districts of the Kathmandu Valley. The number of
other animal bites stayed constant at around 2,000 per year. Inpatient morbidity cases
ranged between 1 and 28 per year, while inpatient mortality cases ranged between 0 and 6
per year. However, data from the EDCD showed that there were nearly 100 rabies deaths
each year [274].
Further information on the rabies burden in Nepal is available from the global burden
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of disease studies conducted by the WHO and the Institute for Health Metrics and Eval-
uation (IHME) (Figure 7.3). The available estimates indicate an important decrease in
the annual number of rabies deaths, converging to 200–400 deaths in recent years. The
burden of rabies, expressed in Disability-Adjusted Life Years (DALYs), was estimated by
IHME at 21,643 for the year 2010 [11] and by WHO at 18,587 for the year 2012 [16].
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Figure 7.2: Median number of dog bites reported during 2001–2012 to the Department of
Health Services, Ministry of Health and Population.
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Figure 7.3: Estimated mean number of rabies deaths in Global Burden of Disease studies.
WHO: World Health Organization Global Health Estimates [292]; GBD2010:
Global Burden of Disease 2010 Study [293]; GBD2013: Global Burden of Disease
2013 Study [294].
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7.3.4 Control
Prophylaxis
Production of ARV in Nepal started in 1970 and continues to date. ARV production is
managed by the Central Rabies Vaccine Production Lab (RVPL), which falls under the
DAH, DLS, Ministry of Agricultural Development [272, 273]. Distribution of ARV is han-
dled via the five regional veterinary laboratories, which serve as rabies vaccine banks [295].
Initially, the RVPL produced phenolized 20% sheep brain ARV for pet immunization and
phenolized 5% sheep brain ARV for livestock immunization. In 1983/84, the RVPL started
production of Beta-Propiolactone (BPL) inactivated 5% sheep ARV for human use, and
was able to meet the national demand by 1994 [296, 297]. Following the WHO recommen-
dations, the production of nerve tissue ARV has now been phased out in favour of tissue
or cell culture ARV. The veterinary authority phased out the production of phenolized 5%
nerve tissue ARV in 2003 and that of phenolized 20% nerve tissue ARV in 2004 [296]. The
production of BPL 5% nerve tissue ARV for human use has been phased out in 2006 [272].
To replace the nerve tissue vaccines, the RVPL worked with the Japan International
Cooperation Agency to set up cell culture ARV production facilities [272, 298]. A first
trial batch of cell culture ARV for animal use was produced in 2002 [297], and after fur-
ther development the first commercial batch was released in the market in 2006 under
the trade name “NeJaRab”. However, with a current target of 50,000 doses per year,
the production of NeJaRab does not meet national demand, necessitating the import of
additional ARV for animal use [295, 299]. Further in 2006, a first trial batch of a Vero
cell culture-based ARV for human use was produced, and in 2009, a first trial batch of
hyper-immune serum from sheep was produced [297]. Today, the productions of cell cul-
ture ARV and RIG for human use are still reported to be in trial phase [299]. Nepal is also
reported to be in the process of introducing intradermal rabies vaccination schedules [300].
The Government of Nepal is providing free ARV for human use at government hospitals
and health centres since 2007 [296, 301]. Despite the progress made in ARV production
capacity, Nepal is 100% dependent on import for covering its PrEP and PEP need. For
the three-year period 2013–2015, the Government of Nepal with support from the World
Bank purchased 900,000 ARV vials from an Indian manufacturer, at a total cost of 220
million NRs (1.8 million Euro). This would be sufficient to provide PEP to 30–40,000
people per year [274]. Nevertheless, media reports show that the availability and supply
of government-provided ARV is sometimes insufficient, in the best case forcing people
to resort to the private market for more expensive vaccines or, in the worst case, de-
priving people of PEP. Furthermore, equine or human RIG is available only in clinics in
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Kathmandu, and due to the high cost, mainly used by tourists and expats [276, 302].
Rabies control programmes
Over the past decades, various state and non-state actors have been involved in rabies
control activities in Nepal. The driving force behind many of these projects appears to
have been Dr Durga Datt Joshi, who served various government positions in the health
and agriculture sector, including that of Chief Zoonotic Diseases Control Section. In 1995,
he founded the NZFHRC, a research-oriented NGO which he chaired until his demise in
2013. In recent years, various animal welfare organizations have started engaging in dog
population management and rabies control activities. The most notable such organiza-
tion is the Kathmandu Animal Treatment (KAT) Centre, which has been active in animal
birth control and dog rabies vaccination in Kathmandu since 2004.
The first reference to a rabies control programme in Nepal appears in the CV of Dr
DD Joshi [303]. In 1970, he was member of the coordination committee for a rabies
control programme in street and pet dogs of Kathmandu. However, further information
on this project is lacking. The next historical reference is given in Bo¨gel & Joshi [279]
and Kappeler & Wandeler [304]. In the early 1980s, Dr DD Joshi and Dr Konrad Bo¨gel,
then Chief of the WHO Veterinary Public Health unit, worked out plans for rabies control
projects in Nepal, including a four-year period vaccination campaign, starting with a pilot
project in Lalitpur City. Funds for the pilot project were assured by Ve´te´rinaires sans
Frontie`res, and in June–July 1989, an intensive dog vaccination campaign was conducted
in Lalitpur town, eventually vaccinating around 8400 dogs. This pilot study was preceded
by an Intercountry Practical Training Course on Dog Population Management, organized
in 1986 in Kathmandu by the WHO Regional Office for South-East Asia, and several
extensive dog population studies conducted in 1986 and 1989 [279, 304]. Despite encour-
aging results, however, we could not retrieve any information pointing to a continuation
of the project beyond the pilot phase.
In 2000–2008, the NZFHRC engaged in free dog rabies vaccination campaigns supported
by the Donative Unit for Rabies Vaccine to Nepal, Tokyo, Japan. Mass dog vaccination
and awareness programmes were organized in 24 municipalities across the country, in col-
laboration with the respective local governments. Over the eight-year period, a total of
18,973 dogs and cats were reported to be vaccinated [305–307].
Since 2001, faculty and students at the Cummings School of Veterinary Medicine, Tufts
University, have been involved in rabies control activities in Nepal [308, 309]. Partnerships
have been set up with the NZFHRC, the KAT Centre, the Himalayan College of Agricul-
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tural Sciences and Technology (HICAST), and the Chitwan-based Institute of Agriculture
and Animal Science (IAAS). Based on a workshop organized in April 2001 in Kathmandu,
a concept for a Nepal National Rabies Control Programme was developed, aiming for the
control of rabies in Nepal over a ten-year period. Since 2002, however, Tufts’ efforts have
been refocused on dog sterilization and rabies vaccination capacity building and student
exchanges at IAAS and the KAT Centre5.
In April 2007, the NZFHRC organized a Workshop for Consensus Building amongst
National Alliance Partners to Eliminate Canine Rabies in Nepal and Development of the
National Strategic Plan [310]. Supported by WHO, the aim of the workshop was to de-
velop a National Rabies Control Plan towards control of rabies by 2012 and elimination
by 2027. Following the workshop, an Alliance Group for Rabies Control in Nepal was
established in 2008, comprising the NZFHRC, the KAT Centre, the Veterinary Public
Health Division of the DLS, and the Department of Public Health and Social Welfare
of Kathmandu Metropolitan City. Since then, the Alliance Group has mainly been in-
volved in dog vaccinations in Kathmandu, including the vaccination of 10,000 stray and
community dogs in 2009 [272]. They are also involved in the annual promotion of World
Rabies Day in Kathmandu, an initiative launched by the Global Alliance for Rabies Con-
trol (GARC) in 2007. During this day, free dog vaccination and awareness campaigns are
organized. Currently, World Rabies Day is marked all across Nepal, with the support of
various animal welfare and students organization.
Although the Government of Nepal has been involved in most of the aforementioned
rabies control activities, it lacks a comprehensive and realistic national rabies control strat-
egy. There are currently no legal requirements regarding the vaccination of pet animals
or livestock. Moreover, the EDCD is currently still supplying free strychnine sulfate to
local governments, leading to the elimination of around 20,000 stray dogs each year [305].
Regional and international rabies control initiatives are emerging, which could help
Nepal in its control efforts [311]. The institution of World Rabies Day by the GARC is
just one example, but other initiatives are being launched by the WHO Regional office for
South-East Asia [114, 300], the South Asian Association for Regional Cooperation [275],
and the RIA Foundation [311, 312].
5http://vet.tufts.edu/idgh/ivm/projects/rabies_control.html
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7.4 Discussion
A proper understanding of the epidemiology and impact of rabies is crucial for planning,
implementing and evaluating rabies control programmes. In this review, we tried to gen-
erate the best possible summary of data on animal and human rabies in Nepal. Per year,
rabies is reported to kill about 100 livestock and 100 humans, while about 9,000 animals
and 35,000 humans are reported to receive rabies PEP. However, these estimates very
likely represent serious underestimations of the true rabies burden. Indeed, underreport-
ing is very likely to occur in both the animal and human passive surveillance systems [265].
Illustrative for these problems are the discrepancies in human rabies deaths between the
DoHS Annual Reports and the EDCD reports and the lack of inpatient data from three
districts since the last four years. Further perturbation is introduced by putative cases
typically being diagnosed based on history and symptoms, and not on lab confirmation.
Laboratory confirmation of rabies is currently limited to the Central Veterinary Labo-
ratory, Kathmandu, which sees around 15 human and animal samples a year [291, 299].
Underreporting of human rabies cases may further result from the fact that rabies patients
sometimes prefer to visit traditional healers or prefer to stay home when rabies symptoms
have appeared.
Rabies is estimated to cause around 20,000 DALYs per year (WHO; [11]). This is in line
with the total burden of the three major parasitic zoonoses in Nepal (i.e., cysticercosis,
toxoplasmosis, cystic echinococcosis; [313]), showing that rabies still is a major zoonosis
in Nepal. However, in absence of reliable data, the burden estimates generated by WHO
and IHME are based on extrapolations from neighbouring countries, warranting cautious
interpretation. Only with more reliable local data can these estimates be further refined.
Significant progress has been made in the production of ARV and RIG. The abandon-
ment of nerve tissue vaccines has been successfully mitigated by the production of cell
culture vaccines. Efforts are ongoing to produce ARV and RIG for human use. Neverthe-
less, availability and supply of vaccine remains a matter of concern, especially in remote
areas. Furthermore, it should be clear that prophylaxis alone is not sufficient to control
rabies. Unfortunately, much less success has been made in the implementation of effec-
tive rabies control programmes. Rabies control programmes appear to have been initiated
since the 1970s. Although some individual projects reported successes, the overall impact
has probably been limited due to limited duration and geographical coverage. Different
state and non-state actors have been involved in rabies control over the years, but col-
laboration between these different groups has been limited. Illustrative of this is that
most projects included awareness and mass dog vaccination, but lacked dog population
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management activities such as animal birth control or waste management. Canine rabies
control programmes could further be complemented with praziquantel treatment against
Echinococcus granulosus, another endemic dog-borne zoonosis [313]. Finally, with 80%
of all rabies occurring in the South Asian region [84], several regional control efforts are
emerging, providing new opportunities for rabies control in Nepal.
7.5 Conclusion
Limited data indicate that rabies still is a major zoonosis in Nepal. However, more and
better data are needed, especially from rural areas, to estimate the true burden of animal
and human rabies and to plan, implement and evaluate rabies control programmes. The
current control of rabies is hampered by insufficient vaccine availability across the coun-
try. The way forward for effective rabies control programmes lies in more collaboration,
both within the country and within the region. To accomplish all of these recommenda-
tions, high-level political commitment is required. Making rabies the model zoonosis for
successful control may be a powerful step towards achieving this.
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General discussion
The main objective of this thesis was to unravel the burden of zoonoses in Nepal and to
quantify this burden using the Disability-Adjusted Life Year (DALY) metric. To achieve
this goal, we contributed to a further standardization of the DALY metric. First, we
proposed a stepwise approach for conducting a DALY-based burden of disease study,
thereby defining important concepts such as the disease model (Chapter 3). Next, we
studied sources of uncertainty inherent to DALY calculations and proposed guidelines
for quantifying parameter, model and methodological uncertainty (Chapter 4). Finally,
we developed a free and open-source tool for calculating DALYs and quantifying related
uncertainties (Chapter 5). Based on the guidelines and tools developed in these first
chapters, we then went on to accomplish the main objective of the thesis. We reviewed the
occurrence of parasitic zoonoses in Nepal, and quantified the disease burden due to cystic
echinococcosis, neurocysticercosis, and congenital toxoplasmosis (Chapter 6). In addi-
tion, we reviewed the epidemiology, burden and control of rabies in Nepal (Chapter 7).
In this chapter we will place our findings in a broader perspective, discuss the main
limitations of the thesis and present avenues for future research.
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8.1 Towards a standardization of the DALY metric
With the advent of the Global Burden of Disease (GBD) 2013 study, the DALY metric
will continue to play a central role in global health. In addition, individual DALY-based
disease burden studies continue to emerge. However, comparability of estimates across
studies is not guaranteed, leading to “error” sources of variability. Our work contributed
to identifying these sources of methodological variability, but definitely did not manage to
resolve the lack of comparability across studies. Moreover, it is not likely that this problem
will be solved in the near future. Indeed, even though the GBD 2013 study will include
nearly 300 causes of ill health, there will still be many diseases and conditions not covered,
including important zoonoses such as toxoplasmosis. Furthermore, even though the GBD
2013 estimates will have a high degree of internal consistency, their external validity is
not guaranteed. The large discrepancy in rabies death estimates between the GBD 2010
and GBD 2013 studies for instance indicates that GBD estimates are highly dependent on
the applied data sources and methodologies and cannot be considered as gold standard.
Independent disease burden studies will therefore continue to be required. Ideally, the
findings from Chapter 4 could lead to the development of a reporting guideline for these
different studies, in line with the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) statement for systematic reviews and meta-analyses [38] or the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) state-
ment for observational studies [314]. Such a check list of assumptions would not resolve
comparability issues, but would at least increase methodological transparency. The DALY
Calculator presented in Chapter 5 should be further developed, allowing for more com-
plex disease models. Developing a user-friendly online interface to the DALY Calculator
would allow the tool to gain a much wider audience.
DALYs were introduced over 20 years ago [15]. However, there has been relatively little
methodological research on the DALY metric and its assumptions and data needs. Two
issues deserve special attention, i.e., the problem of multimorbidity and the extrapolation
of health statistics. In addition, it is important to acknowledge some inherent limitations
of the DALY metric and of summary measures of population health (SMPH) in general.
8.1.1 Accounting for multimorbidity
The co-occurrence of two or more medical conditions in the same individual is not un-
common, especially in the elderly [315]. In medical literature, this phenomenon is called
multimorbidity. When there is an underlying index disease resulting in multimorbidity,
one typically uses the term comorbidity [315]. In DALY calculations, multimorbidity may
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lead to an overestimation of the morbidity component, the Years Lived with Disabil-
ity (YLD). Assume, for instance, a patient with both a moderate osteoarthritis of the
shoulder (DW = 0.114) and a moderate Chronic Obstructive Pulmonary Disease (COPD;
DW = 0.192) [14]. Without correcting for multimorbidity, the DW for this patient would
implicitly be calculated as the sum of both DWs, i.e., 0.144 + 0.192 = 0.336. However,
assuming that DWs, and thus reductions in Health-Related Quality of Life (HRQoL), add
up, is not necessarily correct. Furthermore, additivity could lead to a multimorbid DW
that is larger than 1, i.e., a situation “worse than death”.
Different methods have been described to account for multimorbidity and overcome the
limitations of the additive approach [316]. In the maximum limit or worst case approach,
the multimorbid DW is set equal to the highest DW of the individual conditions. For
our patient, this would result in a DW of 0.192, i.e., that of COPD. In the multiplicative
approach, the multimorbid DW is calculated as 1−∏ (1−DWi), with DWi the individual
DWs. For our patient, this would result in a DW of 1 − (1 − 0.114)(1 − 0.192) = 0.284.
Other researchers used a regression approach to decompose the effects of multimorbid-
ity on HRQoL [61, 62]. Similar decomposition methods have been used to examine the
contribution made by causes of disability to differences in healthy life expectancy [317]
or disability prevalence [318]. Unlike the classical DALY approach, these methods al-
low for a “background” burden, i.e., disability in subjects without a reported disease.
Unfortunately, decomposition methods only allow to study the contribution of multiple
causes to overall health, but do not allow to obtain a DW for an arbitrary set of conditions.
Although these possible correction methods result in theoretically sound DWs, i.e.,
bounded between 0 and 1, their practical validity remains unclear. Indeed, in a comparison
of theoretical and observed multimorbid DWs, measured using the EQ-5D questionnaire,
the maximum limit model appeared to perform worst, while both the maximum limit and
multiplicative approach provided a bad fit in the case of mild to moderate pre-existing
disease [316]. As it is not realistic that all possible multimorbid DWs can be obtained
through health surveys, further research is needed to develop appropriate methods for
estimating DWs for an arbitrary set of conditions.
In addition to the appropriate multimorbid DW, calculating YLDs also requires data
on the prevalence or incidence of the multimorbid condition. Ideally, this information
should come from a population-based health survey. However, due to the large number
of possible causes of ill health, it is practically impossible to measure all possible diseases
and conditions in a population sample [319]. In absence of such information, one has to
estimate the prevalence or incidence of multimorbidity from the prevalence or incidence
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of the individual diseases. In the GBD 2010 and GBD 2013 studies, the prevalence of
multimorbidity was estimated by assuming independence between the prevalence of the
individual diseases [1, 320]. In our example, this would mean that the prevalence of the
given multimorbidity would equal the product of the prevalence of moderate shoulder
arthritis and the prevalence of moderate COPD. Murray et al. [1] argue that the error
associated with the independence assumption is minimal when this assumption is applied
within each specific age–sex group. However, there is little evidence to support this
assumption. Furthermore, there has been no research on methods for estimating the
incidence of multimorbid conditions from the individual incidences or prevalences.
8.1.2 Estimating health statistics
In disease burden studies, it is often necessary to extrapolate data from populations and
time periods that are not necessarily comparable to the concerned population and refer-
ence year. Obviously, this is not only a problem for DALY-based disease burden studies.
Nevertheless, there has been little research on the extrapolation of health statistics and
the related uncertainties. In general, we can distinguish two approaches for filling gaps
in health statistics, i.e., statistical, top-down models, and mechanistic, bottom-up models.
Statistical models use available data to estimate missing data. Maertens de Noordhout
et al. [321] for instance used a random effects model to extrapolate available listeriosis
incidences to countries that lacked such data. The random effect used was World Health
Organization subregion, assuming that countries within a given subregion have a similar
incidence of listeriosis. Further extending such models by including covariates or fixed
effects would lead to mixed effects models. Such models were frequently used in the GBD
2010 and GBD 2013 studies [1, 320]. Rabies mortality, for instance, was modelled based
on the covariates “health system access” and “population density”. In addition, for its
overall mortality estimates, the GBD 2010 and GBD 2013 studies applied a three-stage
approach consisting of non-linear mixed effects regression, spatial-temporal smoothing of
residuals, and Gaussian process regression [294]. Despite the undeniably large impact
of these models on the resulting health estimates, there has been little research on their
performance. Recently, McDonald et al. [322] compared Bayesian random and mixed
effects regression models for imputing missing country-level incidence rates, and found
that the inclusion of informative covariates could improve model performance, but that
results should be appraised carefully. Further research, e.g., through simulation studies,
is needed to better understand the performance of statistical models and the reliability
of the resulting health estimates.
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Mechanistic models, sometimes referred to as bottom-up or a priori models, provide an
alternative means of estimating health statistics. These models are based on an under-
standing of the disease dynamics, and predict disease occurrence from information on the
presumed drivers of disease. Kanobana et al. [323] for instance proposed an agent-based
model for human toxocarosis. Based on information on environmental contamination with
Toxocara spp. eggs, larvation of eggs and age-related contact with eggs, the model pre-
dicted Toxocara antibody positivity in children. To our knowledge, however, such models
and their estimated health statistics have not yet been used in disease burden studies.
8.1.3 General limitations of DALYs and summary measures of
population health
The DALY metric has been developed to compare disease-specific burdens across popula-
tions or time periods. As a result, when DALYs are generated for one or a selected group
of diseases, as was the case in our work, comprehensive comparisons are not possible.
Indeed, the thus obtained DALYs only help to prioritize among the considered diseases,
but ignore the overall importance (or lack thereof) of the group of considered diseases.
Ideally, DALYs should therefore be calculated within an internally consistent framework
covering the entire disease spectrum and multiple time points, allowing for trends over
time to be assessed. Unfortunately, such studies are currently lacking in most countries,
including Nepal. Likewise, as a disease-specific measure, the DALY is less well suited to
provide an overview of the general health status of a population. Indeed, quantifying the
total disease burden of a population would require DALYs to be calculated for an exhaus-
tive set of diseases. Other SMPH, such as the Disability-Free Life Expectancy, have been
developed to quantify and monitor general population health, and may therefore be more
suitable when disease-specific burdens are not of prime interest. Finally, as the DALY
was developed to combine morbidity and mortality in a single estimate, it avoids the
question of whether improvements in morbidity rather than mortality should be pursued.
A recent study by the Belgian Health Care Knowledge Centre (KCE) showed that the
Belgian general population prefers improvements in quality of life over extensions of life
expectancy [324]. Whether or not the same preferences prevail in countries with lower life
expectancy, such as Nepal, remains unclear.
Certain limitations of the DALY metric are common to the larger group of SMPH. As
synthetic measures, the calculation of SMPH is more complex, involving the combination
of multiple input parameters. When one of these input parameters is biased, the SMPH
will therefore also be biased. A crucial component in most SMPH is the weighting factor
for quality of life, or loss thereof. As quality of life is a phenomenon that cannot be
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measured directly, different estimation methods have been proposed, inherently leading
to different values. Haagsma et al. [57] review methodologies for deriving disability weights
for DALY calculations. Furthermore, SMPH reflect by definition only the health impact
of diseases. Especially for zoonotic diseases, however, the economic impact may also be
significant, as not only health-related costs add to the economic burden, but also costs
related to impaired animal health and prevention and control in the veterinary sector.
The negligible global health impact of trichinellosis, for instance, is in sharp contrast to
the significant economic losses due to surveillance in pigs [325]. From an economic point
of view, public health policy should aim at maximizing population health and welfare
with the healthcare resources available [326]. SMPH may assist in achieving allocative
efficiency, i.e., the optimal mixture of healthcare programmes that maximizes overall
population health and welfare. They do not assist in achieving technical efficiency, i.e., the
optimal physical relation between available resource inputs and a given health outcome.
8.2 Burden of zoonoses in Nepal
This thesis contributed to an improved understanding of the epidemiology and burden of
zoonoses in Nepal. The work also demonstrated that even without comprehensive and
efficient surveillance systems, it is possible to unravel the burden of neglected diseases and
break the vicious cycle of neglect. In this respect, the current work has served as a guiding
example for the Country Studies Task Force of the WHO’s Foodborne Disease Burden
Epidemiology Reference Group (FERG), which aims to provide guidance for conducting
national foodborne disease burden assessments [327].
Figure 8.1 shows the combined results of Chapter 6 and Chapter 7, highlighting the
importance of rabies, both at the population-level and the patient-level.
However, our work has been limited by the fact that only the health burden was quanti-
fied, and not the economic burden. The economic impact of zoonoses may be significant,
as it not only results from expenses in the medical sector, but also from productivity
losses and treatment and control costs in the veterinary sector [105, 108]. The high cost
related to the purchase of anti-rabies vaccines (Chapter 7) suggests that zoonoses do
impose a significant economic burden to the Nepalese society. Further research on the
economic impact of zoonotic diseases is therefore encouraged.
In addition, by only focusing on parasitic zoonoses and rabies, we only covered one part
of the large spectrum of zoonotic diseases. Indeed, over 800 pathogens have been defined
as zoonoses, and it is believed that over 60% of all emerging infectious diseases are of
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zoonotic nature [112, 328]. This Section aims to provide a more comprehensive picture of
the burden of zoonoses in Nepal, by drawing upon the GBD and FERG studies.
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Figure 8.1: Population-level (DALY[0;0] per year) versus individual-level burden (DALY[0;0]
per symptomatic case) in Nepal, 2000–2010.
8.2.1 Foodborne zoonoses
In 2006, the World Health Organization (WHO) launched the Initiative to Estimate the
Global Burden of Foodborne Disease. One year later, FERG was established, a group of
experts that were tasked with carrying forward the Initiative [329]. FERG established
task forces for quantifying the burden of foodborne diseases due to parasitic agents, bac-
terial and viral enteric agents, and chemical and toxic hazards. Several of these agents are
entirely or partly of zoonotic nature. Table 8.1 shows the number of deaths and DALYs
estimated by FERG for different foodborne zoonoses in Nepal. According to these esti-
mates, the highest burden is imposed by non-typhoidal salmonellosis and campylobacte-
riosis. There further appears to be a large uncertainty on the burden of brucellosis and
listeriosis [330]. Cryptosporidium spp. is the parasite with the highest burden, although
this burden is probably largely due to anthroponotic transmission, as discussed in Chap-
ter 6. The burden of cysticercosis and cystic echinococcosis is in line with our estimates.
The burden of congenital toxoplasmosis is significantly lower than our estimate, but this
is mainly because stillbirths were not included in the FERG estimates [331].
101
General discussion
8
Table 8.1: Deaths and Disability-Adjusted Life Years (DALYs) with corresponding 95% Cred-
ibility Intervals (CrI) for foodborne zoonoses in Nepal estimated by the Foodborne
Disease Burden Epidemiology Reference Group
Zoonosis Deaths (95% CrI) DALYs (95% CrI)
Parasitic foodborne zoonoses
Cryptosporidiosis* 248 (128–504) 18,885 (8628–41,720)
Cysticercosis 149 (89–230) 11,816 (8475–15,825)
Toxoplasmosis, acquired 0 (0–0) 8193 (5597–11,086)
Ascarosis* 18 (0–85) 5065 (3247–10,330)
Toxoplasmosis, congenital 7 (3–13) 2387 (1224–4081)
Giardiosis* 0 428 (60–1237)
Cystic echinococcosis 4 (1–8) 320 (157–570)
Fasciolosis 0 19 (6–47)
Paragonimosis 0 18 (5–47)
Alveolar echinococcosis 0.2 (0–0.5) 6 (1–21)
Trichinellosis 0 0.20 (0.07–0.35)
Bacterial foodborne zoonoses
Salmonellosis, non-typhoidal 544 (331–1039) 38,274 (20,604–82,567)
Campylobacteriosis 244 (109–508) 22,102 (10,106–45,484)
Brucellosis 152 (0–986) 9672 (2–64,153)
Listeriosis 26 (0–149) 968 (0–5538)
Bovine tuberculosis 8 (3–16) 470 (192–902)
STEC infection** 2 (0–8) 184 (10–678)
*Not 100% foodborne
**STEC: Shiga-toxin producing Escherichia coli
8.2.2 Vector-borne zoonoses
In recent years, vector-borne zoonoses have emerged or re-emerged in many geograph-
ical regions, partly driven by habitat and climate changes [332]. In Nepal, Japanese
Encephalitis (JE) appears to be the best-studied vector-borne zoonosis. JE is caused
by a mosquito-borne flavivirus and transmitted by Culex tritaeniorhynchus and related
mosquitoes that lay eggs in rice paddies and other open water sources. Pigs and aquatic
birds are the main vertebrate amplifying hosts. JE mainly affects children, and induces
an encephalitis that may lead to neurological sequelae or even death [333]. JE was first
recorded in Nepal in 1978. Nepal launched an extensive laboratory-based JE surveillance
in 2004 and introduced mass immunizations in 2005 [334]. Anti-JE vaccination is also
included in the National Immunization Programme, reaching a coverage of 87% [274]. In
102
8General discussion
2006, there were nearly 300 recorded JE cases, dropping to nearly 200 in 2010 and 129
in 2012/13 [274, 334]. Likewise, the number of recorded JE deaths dropped from 42 in
2006 to 1 in 2010 [334]. JE is not included in the GBD 2010 and GBD 2013 studies.
Earlier WHO Global Health Estimates however did include JE: for the year 2004, the
WHO estimated 174 JE deaths and 10,708 DALY[1;0.03]1.
Information on other vector-borne zoonoses is very limited. Murine typhus, due to
Rickettsia typhi, and scrub typhus, due to Orientia tsutsugamushi, appear to be common
causes of febrile illness in Nepalese [335–338]. Recently, the first three cases of chikungunya
fever have been reported, indicating that this zoonosis may be emerging in Nepal [339].
8.2.3 Other zoonoses
Case reports and hospital-based studies indicate the presence of various other zoonoses
in Nepal. However, the available information is typically insufficient to give a clear idea
of their actual impact on population health. From June 2009 to March 2010, pandemic
(H1N1) 2009 virus was confirmed in 172 respiratory samples submitted to the National
Public Health Laboratory [340], and till May 2010, three deaths were reported [341].
Leptospirosis was confirmed in nearly 10% of hepatitis and febrile illness cases [335, 336,
342], and has been recognized as an important differential diagnosis of acute encephalitis
syndrome [343]. Hepatitis E Virus has been studied as a cause of morbidity and death
during pregnancy [344, 345] and as a cause of hepatitis in travellers [346]. Kimura &
Ohnishi, finally, reported a patient with Q fever who had recently visited rural areas in
Nepal and Tibet [347].
8.2.4 Conclusion
The available information shows that several zoonotic diseases are endemic to Nepal. The
zoonoses with the highest public health burden are non-typhoidal salmonellosis, campy-
lobacteriosis, toxoplasmosis, cysticercosis and rabies. Except for cysticercosis, however,
there has been relatively little research on the epidemiology and burden of these zoonoses.
There is a need for more comprehensive burden studies, generating comparable burden
estimates. The inclusion of non-typhoidal salmonellosis, campylobacteriosis and toxoplas-
mosis in the GBD studies would be an important step towards achieving this. Further-
more, it is also important to note that the Millennium Development Goals (MDGs) and
other global health initiatives have had an important impact on the better measurement
of population health [348]. With the deadline for the MDGs in sight, the international
1http://www.who.int/healthinfo/global_burden_disease/estimates_country_2004_2008/en/
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community is currently preparing the post-2015 development agenda. An Open Working
Group under the aegis of the United Nations drafted a list of 17 Sustainable Development
Goals (SDGs)2, which will be proposed for adoption at the SDG Summit in September
2015. SDG 3 aims to “ensure healthy lives and promote well-being for all at all ages”,
and specifically addresses zoonotic and other neglected diseases in subgoal 3.3:
“by 2030 end the epidemics of AIDS, tuberculosis, malaria, and neglected trop-
ical diseases and combat hepatitis, water-borne diseases, and other communi-
cable diseases”
When endorsed, the SDGs might therefore provide an impetus for improving the mea-
surement of the zoonoses burden in Nepal and other endemic countries. Nevertheless,
discussion is still ongoing on the targets and indicators to be used in the SDG monitoring
framework for most neglected tropical diseases [349].
8.3 Control of zoonoses in Nepal
The ultimate aim of disease burden estimates is to inform decision makers on setting the
right research and control priorities. In this section we summarize recent zoonoses control
activities in Nepal and discuss the contribution of our and other burden estimates.
8.3.1 Zoonoses control activities
The Zoonotic Disease Sub-section of the Epidemiology and Disease Control Division
(EDCD), Department of Health Services, Ministry of Health and Population, is responsi-
ble for the prevention and control of zoonotic diseases. The Sub-section was established in
1979 as “Veterinary Public Health” Section [350]. The main activities of the Sub-section
are related to the purchase and distribution of anti-snake venom serum and anti-rabies
vaccines, which are both distributed free of charge through government hospitals [274].
Rabies control activities are discussed in more detail in Chapter 7. The EDCD further
managed to control JE through mass vaccination campaigns and the inclusion of JE in
the National Immunization Programme [274, 334].
The main legislations related to zoonoses control are the Animal Health and Live-
stock Services Act 1998 and the Animal Slaughterhouse and Meat Inspection Act 1999.
These acts and their rules and regulations make provisions related to animal quarantine,
slaughter of animals, sale of animal products, etc. The Animal Slaughterhouse and Meat
2https://sustainabledevelopment.un.org/focussdgs.html
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Inspection Act, for instance, states that all slaughter animals and meat should be exam-
ined by a meat inspector [283]. However, despite its promulgation more than 15 years
ago, the Act has not yet been officially enforced. Unstable governments due to continuous
political transitions, along with insufficient public awareness and deficiencies in the Act
itself are believed to be the main reasons for its non-implementation [351, 352].
Since 2007, Nepal has been granted two World Bank projects to support its zoonoses
control activities. The Avian Influenza Control Project3 ran from January 2007 to July
2011, aiming to increase capacity to respond to a potential pandemic of highly pathogenic
avian influenza (HPAI). In the spirit of a “One Health” approach, the project was man-
aged collaboratively by the Department of Livestock Services (DLS) and the Department
of Health Services (DoHS). The project established an effective system for identifying and
controlling outbreaks of HPAI in birds, but had only a modest impact on preparedness
for human influenza epidemics and pandemics [353]. From April 2012 to March 2014, a
follow-up World Bank project was run, entitled the Zoonoses Control Project4. One of the
main outcomes of this project was the definition of a set of “priority zoonoses” for Nepal.
Based on certain criteria, such as food safety, morbidity, mortality, risk of emergence,
and nationally available financial resources for control, the following eight zoonoses were
identified as priority zoonoses: HPAI, brucellosis, leptospirosis, toxoplasmosis, cysticerco-
sis, cystic echinococcosis, (bovine) tuberculosis and rabies. Further outputs included the
establishment of a One Health Hub5 between representatives of the DLS and the DoHS,
and the redefinition of the National Avian Influenza Information Committee to National
Zoonoses Information Committee [354].
8.3.2 Impact of burden estimates on policy
Although our work has been picked up by certain media6,7, we have no evidence that our
work managed to inform decision makers. Moreover, we see a clear disconnect between
the recent prioritization of zoonoses by the Government of Nepal and our findings. For
four of the eight priority zoonoses, we either found a low burden or insufficient data to
estimate the burden. On the other hand, FERG identified two non-prioritized zoonoses,
i.e., non-typhoidal salmonellosis and campylobacteriosis, as major foodborne zoonoses.
In the report of a WHO Regional Meeting on Zoonotic Diseases [355], this disconnect
3http://www.worldbank.org/projects/P100342/avian-influenza-control-project?lang=en
4http://www.worldbank.org/projects/P130089/zoonoses-control-project-zcp?lang=en
5http://www.hubnet.asia/sites/nepalonehealthhub
6http://www.thehimalayantimes.com/fullNews.php?headline=Better+zoonoses+surveillance+
stressed&NewsID=408443
7http://www.scidev.net/south-asia/health/news/animal-borne-parasites-plague-nepal.
html
105
General discussion
8
between evidence and policy was phrased as follows:
“It was difficult to understand how hydatidosis, toxoplasmosis, brucellosis and
leptospirosis were considered as priority zoonoses in Nepal when the magnitude
of the disease problem and socioeconomic impact of selected diseases were not
known.”
The limited impact of our work can perhaps be seen as the main limitation of this the-
sis. We therefore strongly recommend to include capacity building and knowledge transfer
activities in similar, future projects. In our case, this could have been through a work-
shop with relevant stakeholders, during which we could have introduced the DALY metric
and presented our burden estimates. Nevertheless, when placing knowledge transfer in
a broader perspective, we must acknowledge that incorporating scientific evidence in the
policy cycle is not a straightforward undertaking [356]. Even if we would have presented
our results directly to the concerned stakeholders, our findings would not necessarily have
been translated into policy. Indeed, although evidence-based policy making is an impor-
tant aspirational goal, only a small proportion of research has the policy impact it might
have [357]. The complexity of DALYs and other synthetic measures of population health
may make them less intuitive for policy makers to use. Different methodologies for gen-
erating DALYs and different ways of presenting DALY estimates (e.g., population versus
patient level, uncertainty intervals), might further impede appreciation by the concerned
policy makers. Capacity building, i.e., generating an understanding and appreciation of
the metric by health officials, is therefore an important driver of policy transfer. Exem-
plary of this link is the current importance of DALYs for health policy in the Netherlands,
which is driven by an early adoption of the metric by scientists working at the Dutch Na-
tional Institute for Public Health and the Environment [12]. In addition to the complexity
of the metric, DALYs only tell one part of the story, while prioritizations in the health
sector are ideally guided by a variety of inputs, including economic impact and availability
of effective control measures. In practice, however, decisions often have to be made in
absence of such information, or are influenced by personal interests of decision makers and
stakeholders. On the other hand, burden estimates are sometimes merely demanded by
decision makers to back up current control activities [358]. Notwithstanding the possible
disconnect between burden estimates and policy, we do believe that it is of paramount
importance to continue generating disease burden estimates. Only then can we gain the
knowledge that is required to take the right actions.
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8.4 Perspectives
This thesis highlighted the following avenues for further research:
Development of a reporting guideline for DALY-based disease burden studies.
In line with the PRISMA or STROBE statements, a checklist of assumptions would
increase methodological transparency in DALY-based disease burden studies.
Development of a user-friendly DALY calculation tool. A user-friendly online
interface to the DALY Calculator would allow the tool to gain a wider audience.
Improved estimation of the burden of multimorbid conditions. Appropriate
methods are required to estimate disability weight, prevalence and incidence of an
arbitrary set of conditions.
Improved estimation of health statistics. More evidence is needed on the perfor-
mance of statistical models and the possible use of mechanistic models for filling
gaps in health statistics.
Economic burden of zoonoses in Nepal. Information on financial losses in both the
medical and veterinary sector are needed to inform decision makers.
Comparable burden estimates. Comprehensive burden studies are needed to assess
and monitor the burden of the identified top zoonoses.
Capacity building and knowledge transfer. Future projects should emphasize the
transfer of skills and knowledge to the concerned stakeholders, such that burden
estimates can truly be used to guide policy.
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Summary
Chapter 1 provided the background for this thesis.
The main goal of public health policy is to promote, enhance and protect population
health. This requires information on the health status of the population, often referred to
as the “burden of disease”. Population health is a multifactorial phenomenon with many
facets. As a result, the disease burden of a population can be described by a variety of
indicators. As current health policy requires a global overview of public health, combining
morbidity and mortality and taking into account health-related quality of life, so-called
summary measures of population health (SMPH) are gaining wider importance.
Driven by the influential Global Burden of Disease projects initiated in the early 1990s,
the Disability-Adjusted Life Year (DALY) has become the dominant SMPH. The DALY
is a health gap measure, reflecting the number of healthy life years lost due to disease
and death. In the DALY philosophy, every person is born with a certain number of life
years potentially lived in optimal health. People may lose these healthy life years through
living with illness and/or through dying before a reference life expectancy.
The importance of burden of disease estimates for health policy in Nepal becomes evi-
dent from recent policy documents and recommendations. The Second Long-Term Health
Plan 1997–2017 was the first document to recognize the importance of prioritizing health
sector needs, motivated by the scarce human, financial and physical resources available.
Notwithstanding the importance of disease burden estimates, Nepalese DALYs are scarce
and not rooted in local data. Especially for zoonotic and other neglected diseases, this
may lead to a vicious cycle of indifference, under-recognition and under-funding.
Chapter 2 introduced the rationale and objectives of this thesis. The main objective
of this thesis was to unravel the burden of zoonoses in Nepal and to quantify this burden
using the DALY metric. To achieve this goal, we contributed to a further standardization
of the DALY metric.
Although the philosophical and methodological aspects of the DALY calculation have
been described (and debated) in great detail, the steps preceding the actual calculation
remained less well documented. In Chapter 3, we therefore proposed a stepwise ap-
proach for conducting a DALY-based disease burden study, consisting of the following
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five consecutive steps: Study population definition; Disease model definition; Data collec-
tion; Data adjustment; and DALY calculation.
Nearly every DALY estimation is subject to data uncertainty and modelling choices.
The resulting DALY estimate is therefore hardly ever a single, fixed value, defined with
perfect accuracy and precision. In Chapter 4, we studied sources of uncertainty inherent
to DALY calculations through a systematic review of DALY-based disease burden studies.
Of the 228 studies published between 1994 and 2013, only 105 (46%) had performed some
sort of uncertainty quantification. Identifying, quantifying and analysing uncertainties
should become a standard part of DALY calculations. We recommend probabilistic sensi-
tivity analysis for quantifying parameter uncertainty and scenario analyses for quantifying
model and methodological uncertainties.
To our knowledge, there are no standardized tools available for stochastic DALY cal-
culation. We therefore designed a free and open-source tool for calculating DALYs that
allows for the incorporation of input uncertainty and the computation of DALY credibil-
ity intervals through Monte Carlo simulations. Chapter 5 provides an overview of the
functionalities of this tool, called the DALY Calculator. Further work is needed to increase
the flexibility and user-friendliness of the tool.
Based on the guidelines and tools developed in these first chapters, we then went on
to accomplish the main objective of the thesis. In Chapter 6, we reviewed the occur-
rence and burden of parasitic zoonoses in Nepal. Between 2000 and 2012, the highest
annual burden was imposed by neurocysticercosis and congenital toxoplasmosis, followed
by cystic echinococcosis. Nepal is endemic for several other parasitic zoonoses, but these
probably have a much lower population burden. We identified several critical data gaps
and highlighted the need for enhanced surveillance of the identified endemic parasitic
zoonoses.
In addition, we reviewed the epidemiology, burden and control of rabies in Nepal in
Chapter 7. Limited data indicate that rabies still is a major zoonosis in Nepal. How-
ever, more and better data are needed, especially from rural areas, to estimate the true
burden of animal and human rabies. The current control of rabies is hampered by in-
sufficient vaccine availability across the country and limited collaboration, both within
the country and within the region. To overcome these hurdles, high-level political com-
mitment is required. Making rabies the model zoonosis for successful control may be a
powerful step towards achieving this.
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In Chapter 8, finally, we placed our findings in a broader perspective, discussed their
main limitations and presented avenues for future research.
Our work contributed to identifying sources of methodological variability in DALY es-
timations, but did not manage to resolve the lack of comparability across studies. The
development of a checklist of assumptions, based on our work, could increase methodolog-
ical transparency in DALY-based disease burden studies. Further methodological research
needs to focus on the problem of multimorbidity and the extrapolation of health statistics.
Our work also contributed to an improved understanding of the epidemiology and bur-
den of zoonoses in Nepal and highlighted the importance of rabies, both at the population-
level and the patient-level. However, our work has been limited by the fact that only the
health burden was quantified, and not the economic burden. Furthermore, by focusing on
parasitic zoonoses and rabies, we covered only one part of the large spectrum of zoonotic
diseases. Further evidence on the burden of foodborne zoonoses in Nepal is available
from the WHO Foodborne Disease Burden Epidemiology Reference Group. Combining
all available evidence shows that the zoonoses with the highest disease burden in Nepal are
non-typhoidal salmonellosis, campylobacteriosis, toxoplasmosis, cysticercosis and rabies.
The ultimate aim of disease burden estimates is to inform decision makers on setting
the right research and control priorities. However, we have no evidence that our work
managed to inform decision makers. Future, similar projects should therefore emphasize
capacity building and knowledge transfer. Notwithstanding the possible disconnect be-
tween burden estimates and policy, we do believe that it is of paramount importance to
continue generating disease burden estimates. Only then can we gain the knowledge that
is required to take the right actions.
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Le Chapitre 1 fournit le contexte de cette the`se.
L’objectif principal de la politique de sante´ publique est de prote´ger et promouvoir
la sante´ de la population. Ceci ne´cessite des informations sur le statut de sante´ de la
population, commune´ment appele´ « le fardeau de la maladie ». La sante´ de la population
est un phe´nome`ne multifactoriel qui comprend e´norme´ment de facettes. En re´ponse a`
ceci, le fardeau de la maladie d’une population peut eˆtre de´crit a` l’aide d’une varie´te´
d’indicateurs. Ainsi, comme la politique de sante´ actuelle requie`re une vue d’ensemble de
la sante´ publique combinant morbidite´ et mortalite´ et prenant en compte la qualite´ de
vie lie´e a` la sante´, les mesures synthe´tiques de la sante´ publique gagnent en importance.
Le « Disability-Adjusted Life Year » (DALY) a e´te´ cre´e´ au de´but des anne´es nonante
par les projets d’e´valuation du fardeau mondial des maladies et est actuellement la mesure
synthe´tique la plus utilise´e. Le DALY est une mesure de l’e´cart de sante´, refle´tant le nom-
bre d’anne´es de vie en bonne sante´ perdues a` cause d’une maladie ou d’un de´ce`s. Dans la
philosophie du DALY, chaque personne est ne´e avec un certain nombre d’anne´es de vie
potentiellement ve´cues dans une sante´ optimale. Les personnes peuvent perdre ces anne´es
de vie en bonne sante´ suite a` une maladie et/ou un de´ce`s avant l’espe´rance de vie atten-
due. L’importance des estimations du fardeau de la maladie pour la politique de sante´
au Ne´pal devient manifeste depuis la publication de re´cents documents et recommanda-
tions politiques. Le deuxie`me projet de sante´ a` long terme de 1997-2017 e´tait le premier
document a` reconnaitre l’importance de prioriser les besoins de sante´ sectoriels, motive´
par la rarete´ des ressources humaines, financie`res et physiques. Malgre´ l’importance des
estimations du fardeau de la maladie, les DALYs ne´palais sont rares et non ancre´s dans
les donne´es locales. Particulie`rement pour les zoonoses et les autres maladies ne´glige´es,
ce qui peut mener a` un cercle vicieux d’indiffe´rence, de sous-reconnaissance et de sous-
financement.
Le Chapitre 2 introduit le rationnel et les objectifs de cette the`se. L’objectif principal
de cette the`se e´tait d’e´claircir le fardeau des zoonoses au Ne´pal et de quantifier ce fardeau
en utilisant le DALY comme mesure. Afin d’atteindre cet objectif, nous avons contribue´
a` une meilleure standardisation du DALY.
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Malgre´ que les aspects philosophiques et me´thodologiques du calcul de DALY ont e´te´
de´crits (et de´battus) en de´tails, les e´tapes pre´ce´dant le calcul meˆme restaient moins bien
documente´es. Dans le Chapitre 3, nous avons donc propose´ une approche par e´tapes
pour e´laborer une e´tude de fardeau de la maladie base´e sur les DALYs comprenant les
cinq e´tapes suivantes: De´finition de la population d’e´tude; De´finition du mode`le de la
maladie; Collecte des donne´es; Ajustement des donne´es; et calcul des DALYs.
Presque chaque estimation de DALY est sujette a` une incertitude dans les donne´es et
a` des choix de mode´lisation. L’estimation de DALY re´sultant de ces choix n’est donc
presque jamais une valeur fixe de´finie avec une pre´cision et une exactitude parfaite. Dans
le Chapitre 4, nous avons e´tudie´ les sources d’incertitudes inhe´rentes aux calculs de
DALY a` l’aide d’une revue syste´matique des e´tudes du fardeau de la maladie base´es sur
le DALY. Sur les 228 e´tudes publie´es entre 1994 et 2013, seulement 105 (46%) avaient
re´alise´ une sorte de quantification de l’incertitude. Identifier, quantifier et analyser les
incertitudes devraient devenir une e´tape standard dans les calculs de DALY. Nous recom-
mandons une analyse de sensibilite´ probabiliste pour e´tudier l’incertitude d’un parame`tre
et des analyses de sce´narios pour quantifier les incertitudes du model et de la me´thodologie.
A notre connaissance, il n’existe aucun outil standard pour le calcul stochastique des
DALYs. Nous avons donc cre´e´ un outil gratuit et open source pour le calcul des DALYs
qui permet d’ajouter des donne´es d’incertitude et de calculer les intervalles de cre´dibilite´
a` l’aide des simulations de Monte Carlo. Le Chapitre 5 fournit une vue d’ensemble des
fonctionnalite´s de l’outil, appele´ le « DALY Calculator ». Du travail supple´mentaire est
encore ne´cessaire pour ame´liorer la flexibilite´ et la convivialite´ de l’outil.
A l’aide des lignes directrices et des outils de´veloppe´s dans ces premiers chapitres, nous
avons ensuite atteint l’objectif principal de la the`se. Dans le Chapitre 6, nous avons
passe´ en revue la survenue et le fardeau des zoonoses parasitaires au Ne´pal. Entre 2000 et
2012, le fardeau annuel le plus e´leve´ e´tait attribue´ a` la neurocysticercose et la toxoplas-
mose conge´nitale, suivies ensuite par l’e´chinococcose kystique. Le Ne´pal est ende´mique
pour plusieurs autres zoonoses parasitaires, mais celles-ci pe`sent probablement un plus
faible fardeau sur la population. Nous avons identifie´ un certain nombre de lacunes en
termes de donne´es et souligne´ la ne´cessite´ de renforcer la surveillance des zoonoses para-
sitaires ende´miques.
De plus, nous avons passe´ en revue l’e´pide´miologie, le fardeau et le controˆle de la rage au
Ne´pal dans le Chapitre 7. Les donne´es restreintes indiquent que la rage reste une zoonose
majeure au Ne´pal. Cependant, des donne´es supple´mentaires et de meilleure qualite´ sont
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ne´cessaires, particulie`rement dans les re´gions rurales, pour estimer le ve´ritable fardeau de
la rage animal et humaine. Le controˆle actuel de la rage et entrave´ par la disponibilite´
insuffisante de vaccins a` travers le pays et la faible collaboration, a` la fois au sein du pays
et dans la re´gion. Afin de reme´dier a` ces obstacles, un engagement politique de haut
niveau est requis. Faire de la rage un mode`le de controˆle de zoonose re´ussi pourrait eˆtre
une e´tape puissante vers l’accomplissement de ceci.
Finalement dans le Chapitre 8, nous avons place´ nos re´sultats dans une perspective
plus large, discute´ leurs principales limitations et pre´sente´ des pistes pour de futures
recherches.
Notre travail a contribue´ a` identifier les sources de variabilite´ me´thodologiques dans les
estimations de DALY mais n’a pas re´ussi a` re´soudre le proble`me du manque de compa-
rabilite´ entre les e´tudes. La mise en place d’une checklist d’hypothe`ses, base´e sur notre
travail, pourrait augmenter la transparence me´thodologique des e´tudes de fardeau de la
maladie base´es sur le DALY. D’autres recherches me´thodologiques doivent se concentrer
sur le proble`me de multimorbidite´ et sur l’extrapolation des statistiques de sante´.
Notre travail a e´galement contribue´ a` ame´liorer la compre´hension de l’e´pide´miologie et
du fardeau des zoonoses au Ne´pal et a souligne´ l’importance de la rage, a` la fois au niveau
de la population qu’au niveau du patient. Cependant, notre travail a e´galement e´te´ limite´
par le fait que seul le fardeau de la sante´ a e´te´ quantifie´ et non le fardeau e´conomique.
De plus, en se focalisant sur les zoonoses parasitaires et la rage, nous avons uniquement
couvert une petite partie du spectre tre`s large des maladies zoonotiques. D’autres infor-
mations concernant le fardeau des maladies zoonotiques d’origine alimentaire au Ne´pal
sont e´galement disponibles via le « Foodborne Disease Burden Epidemiology Reference
Group » de l’OMS. En combinant toutes les donne´es disponibles, nous pouvons affirmer
que la salmonellose non typhique, la campylobacte´riose, la toxoplasmose, la cysticercose
et la rage sont les zoonoses ayant le plus gros impact sur le fardeau des maladies au Ne´pal.
Le but ultime des estimations du fardeau de la maladie est d’informer les de´cideurs
des bonnes priorite´s a` e´tablir dans le domaine de la recherche et du controˆle des mal-
adies. Cependant, nous n’avons aucune preuve que notre travail a re´ussi a` informer les
de´cideurs. Dans le futur, d’autres projets similaires devraient donc mettre l’accent sur le
de´veloppement des capacite´s et le transfert des connaissances. Malgre´ le possible de´calage
entre les estimations de fardeau et la politique, nous croyons qu’il est primordial de con-
tinuer a` ge´ne´rer des estimations de fardeau de la maladie. Alors seulement nous pouvons
acque´rir la connaissance ne´cessaire pour prendre des mesures approprie´es.
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Hoofdstuk 1 schetste de achtergrond van deze thesis.
De hoofddoelstelling van het volksgezondheidsbeleid is om de gezondheid van de bevolk-
ing te beschermen en te bevorderen. Hiervoor is informatie nodig over de gezondheidssta-
tus van de bevolking, ook gekend als de “ziektelast”. Volksgezondheid is multifactorieel en
kent verschillende facetten. Hierdoor kan de ziektelast in een populatie beschreven wor-
den met verschillende indicatoren. Aangezien het hedendaagse volksgezondheidsbeleid
nood heeft aan een globaal beeld van de gezondheid van de populatie, dat zowel ziekte
als sterfte omvat en de levenskwaliteit mee in rekening brengt, winnen zogenaamde syn-
thetische ziektelastindicatoren aan belang.
Onder impuls van de invloedrijke Global Burden of Disease-projecten die begin jaren
’90 werden ge¨ınitieerd, is de Disability-Adjusted Life Year (DALY) uitgegroeid tot de
belangrijkste synthetische ziektelastindicator. De DALY is een gezondheidskloofindicator,
en reflecteert het aantal gezonde levensjaren dat verloren is door ziekte en sterfte. In de
DALY-filosofie wordt iedere persoon geboren met een zeker aantal levensjaren dat in volle
gezondheid geleefd kan worden. Personen kunnen deze gezonde levensjaren verliezen door
te leven met ziekte en/of te sterven voor een bepaalde optimale levensverwachting.
Het belang van ziektelastindicatoren voor het gezondheidsbeleid in Nepal blijkt uit
recente beleidsdocumenten en -aanbevelingen. Het Second Long-Term Health Plan 1997–
2017 was het eerste document dat het belang erkende van de prioritering van behoeften
binnen de gezondheidssector, en dit gemotiveerd door de schaarse personele, financie¨le en
fysieke middelen. Niettegenstaande het belang van ziektelastindicatoren, zijn Nepalese
DALYs eerder schaars en slechts in beperkte mate gesteund op lokale gegevens. Vooral
voor zoo¨notische en andere verwaarlossde ziekten kan dit leiden tot een vicieuze cirkel
van onverschilligheid, onderwaardering en onderfinanciering.
Hoofdstuk 2 introduceerde de motivering en doelstellingen van dit proefschrift. De
hoofddoelstelling van het proefschrift was de ziektelast te wijten aan zoo¨notische ziekten
in Nepal te ontrafelen en te kwantificeren aan de hand van de DALY-parameter. Om deze
doelstelling te bereiken, hebben we eerst bijgedragen aan een verdere standaardisatie van
de DALY-parameter.
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Hoewel de filosofische en methodologische aspecten van de DALY-berekening in detail
beschreven (en bediscussieerd) zijn, zijn de stappen voorafgaand aan de eigenlijke bereken-
ing minder goed gedocumenteerd. In Hoofdstuk 3 hebben we daarvoor een stapsgewijze
aanpak voorgesteld voor een op DALYs gebaseerde ziektelaststudie, bestaande uit de
volgende vijf stappen: Definitie van de studiepopulatie; Definitie van het ziektemodel;
Verzamelen van de nodige gegevens; Correctie van de gegevens; en DALY-berekening.
Bijna elke DALY-berekening is onderhevig aan onzekerheid in de gegevens en subjec-
tieve keuzes in de modellering. De resulterende DALY-schatting is daarom zelden e´e´n
vaste waarde met perfecte nauwkeurigheid en precisie. In Hoofdstuk 4 hebben we bron-
nen van onzekerheid inherent aan DALY-berekeningen bestudeerd aan de hand van een
systematische review van op DALYs gebaseerde ziektelaststudies. Van de 228 studies
gepubliceerd tussen 1994 en 2013, had slechts 105 (46%) enige kwantificering van onzek-
erheid uitgevoerd. Het identificeren, kwantificeren en analyseren van onzekerheden moet
een standaard onderdeel van DALY-berekeningen worden. Wij raden probabilistische
gevoeligheidsanalyse aan voor het kwantificeren van parameteronzekerheid en scenario-
analyses voor het kwantificeren van het model- en methodologische onzekerheden.
Voor het begin van dit doctoraat waren er geen gestandaardiseerde tools beschikbaar
voor stochastische DALY-berekeningen. Daarom hebben we een gratis en open-source tool
voor de berekening van DALY’s ontwikkeld die het mogelijk maakt om via Monte Carlo-
simulaties de onzekerheid in de gegevens om te zetten naar DALY-onzekerheidsintervallen.
Hoofdstuk 5 geeft een overzicht van de functionaliteiten van deze tool, die we de DALY
Calculator genoemd hebben. Verdere aanpassingen zijn nodig om de flexibiliteit en ge-
bruiksvriendelijkheid van de tool te verbeteren.
Op basis van de richtlijnen en tools ontwikkeld in deze eerste hoofdstukken, hebben
we vervolgens de hoofddoelstelling van dit proefschrift verwezenlijkt. In Hoofdstuk 6
hebben we het voorkomen en de ziektelast van parasitaire zoo¨nosen in Nepal bestudeerd.
Tussen 2000 en 2012 waren neurocysticercose en congenitale toxoplasmose verantwo-
ordelijk voor de belangrijkste ziektelast, gevolgd door cystische echinococcose. Nepal
is endemisch voor verschillende andere parasitaire zoo¨nosen, maar deze hebben waarschi-
jnlijk een veel lagere impact op de volksgezondheid. We identificeerden een aantal kritis-
che lacunes in de gegevens en wezen op de noodzaak van een betere surveillance van de
ge¨ıdentificeerde endemische parasitaire zoo¨nosen.
Daarnaast hebben we in Hoofdstuk 7 de epidemiologie, ziektelast en controle van
hondsdolheid in Nepal bestudeerd. De beperkte gegevens wijzen erop dat hondsdolheid
148
12
Samenvatting
nog steeds een van de belangrijkste zoo¨nosen in Nepal is. Er zijn echter meer en betere
gegevens nodig, vooral vanuit rurale gebieden, om de ware impact van hondsdolheid op
dier en mens te kunnen schatten. De controle van hondsdolheid wordt momenteel belem-
merd door onvoldoende beschikbaarheid van vaccins in het hele land, en door de beperkte
samenwerking, zowel binnen het land als binnen de regio. Om deze hindernissen te over-
winnen, is politiek engagement op hoog niveau vereist. Hondsdolheid uitroepen tot model
voor een succesvolle controle van zoo¨nosen zou een krachtige stap kunnen zijn om dit te
bereiken.
In Hoofdstuk 8, tot slot, hebben we onze bevindingen in een breder perspectief
geplaatst, hun belangrijkste tekortkomingen besproken, en mogelijkheden voorgesteld
voor verder onderzoek.
Ons werk heeft bijgedragen aan het bepalen van de methodologische variabiliteit in
DALY-schattingen, maar slaagde er niet in om het gebrek aan vergelijkbaarheid tussen
studies op te lossen. De ontwikkeling van een checklist van methodologische assumpties,
gebaseerd op ons werk, zou de methodologische transparantie in op DALY gebaseerde ziek-
telaststudies kunnen verhogen. Verder methodologisch onderzoek moet zich concentreren
op het probleem van multimorbiditeit en de extrapolatie van gezondheidsindicatoren.
Ons werk heeft ook bijgedragen aan een betere kennis van de epidemiologie en de ziek-
telast van zoo¨nosen in Nepal en heeft het belang benadrukt van hondsdolheid, zowel op
populatieniveau als op patie¨ntniveau. Ons werk was echter beperkt door het feit dat
alleen de impact op de volksgezondheid werd gekwantificeerd, en niet de impact op de
economie. Door te focussen op parasitaire zoo¨nosen en hondsdolheid, hebben we voorts
ook slechts een deel van het brede spectrum van zoo¨nosen aangepakt. Aanvullend bewijs
over de ziektelast van door voedsel overgedragen zoo¨nosen in Nepal werd gegenereerd door
de Foodborne Disease Burden Epidemiology Reference Group van de Wereldgezondheid-
sorganisatie. De combinatie van alle beschikbare schattingen toont aan dat niet-tyfo¨ıde
salmonellose, campylobacteriose, toxoplasmose, cysticercose en hondsdolheid, de zoo¨nosen
met de belangrijkste ziektelast in Nepal zijn.
Het uiteindelijke doel van ziektelastschattingen is om beleidsmakers te helpen bij het
stellen van de juiste prioriteiten voor onderzoek en controle. We hebben echter geen bewijs
dat ons werk er ook effectief in geslaagd is om beleidsmakers te informeren. Toekomstige,
soortgelijke projecten moeten daarom meer aandacht besteden aan capaciteitsopbouw en
kennisoverdracht. Niettegenstaande de mogelijke discrepantie tussen ziektelastschattingen
en beleid, menen we dat het van het groot belang is om ziektelastschattingen te blijven
genereren. Alleen dan kunnen we de kennis genereren die nodig is om de juiste acties te
kunnen ondernemen.
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